FORMULATION INCLUDING AN ADSORBENT MIXED WITH CARRAGEENIN, FOR ORAL DELIVERY AND CONTROLLED RELEASE

专利摘要:
composition, formulation, and use of a formulation The invention relates to a formulation for the delayed and controlled release of an adsorbent in the large intestine of mammals. the formulation includes a carrageenan and an adsorbent such as activated carbon. the invention further relates to uses of this formulation, in particular pharmaceutical uses. in one embodiment, the formulation is used to eliminate or reduce side effects in the intestine, in particular the colon, of pharmaceutical agents that are administered as a treatment for a disorder, but which have side effects when they reach the ileum, the cecum or colon.
公开号:BR112012021275B1
申请号:R112012021275-3
申请日:2011-02-23
公开日:2021-07-27
发明作者:François Lescure；Jean De Gunzburg
申请人:Da Volterra；
IPC主号:

专利说明:

[0001] The invention relates to a formulation for the delayed and controlled delivery of an adsorbent in the large intestine of mammals. The invention further relates to uses of this formulation, in particular pharmaceutical uses. FUNDAMENTALS OF THE INVENTION
[0002] When antibiotics are administered, orally or parenterally, a significant fraction of the administered dose reaches the ileum or colon in an active form and comes into immediate contact with the bacterial population that is present in the colon. The alarming consequences of this have been known for years and are the subject of an ECDC/EMEA Joint Technical Report entitled “The bacterial challenge: time to react, A call to narrow the gap between multidrug-resistant bacteria in the EU and the development of new antibacterial agents” published September 2009. Residual antibiotic exerts selective pressure on bacteria present in the colon and causes the emergence and development of antibiotic resistant bacteria. Because the genetic determinants of resistance to multiple antibiotics are often physically linked onto mobile genetic elements such as plasmids and transposons, treatment with a single antibiotic often selects for the simultaneous presence of multiple antibiotic resistant genes, thus explaining how multidrug resistance -antibiotic can emerge very fast.
[0003] As a result of this process, the patient or animal that has received an antibiotic treatment becomes very quickly and heavily colonized by antibiotic resistant bacteria. This can result in additional interactions complicated by resistant bacteria as well as the spread of resistance to other bacteria, and ultimately to the environment.
[0004] It is now widely accepted that the selection and spread of such resistant bacteria is a major factor that significantly increases the spread of bacterial antibiotic resistance both in the community and in hospitals. Bacterial resistance levels are currently extremely high and are increasing year after year becoming a major public health problem worldwide that can lead to further outbreaks of infections very difficult to treat with antibiotics available in humans or animals.
[0005] In addition to producing antibiotic resistant bacteria, antibiotics that actively target the colon will also profoundly alter the composition of the commensal flora and eliminate susceptible bacterial species. Among these bacteria, susceptible anaerobic bacteria can be eliminated; they are known to play a major physiological role in the gut of normal individuals and animals. For example, they act to prevent colonization by potentially pathogenic exogenous microorganisms such as Clostridium difficile and/or Candida sp, and/or multiresistant exogenous bacteria such as vancomycin-resistant enterococci. It is therefore essential to prevent the elimination of such useful bacteria to prevent adverse effects of antibiotics, which can lead to the appearance of pathological signs and symptoms, such as post-antibiotic diarrhea or the more severe forms of pseudomembranous colitis, genital Candida infections, particularly in women, or antibiotic-resistant systemic infections in hospitalized patients, particularly those in intensive care.
[0006] One way to prevent such adverse effects of antibiotic treatments is to eliminate residual antibiotics that reach the cecum and colon; in recent years there have been two different methods of achieving this goal. One has been the delivery to the intestine of enzymes that specifically degrade antibiotics (such as those described in US20050249716). Alternatively, the formulation of an adsorbent for site-specific intestinal delivery has been proposed in applications WO2006/122835 and WO2007/132022. The adsorbent would work by sequestering the antibiotic before it can affect susceptible bacteria in the cecum and colon. This method would allow to broaden the spectra of antibiotics that can be eliminated when compared to previous methods based on specific antibiotic enzymes. Adsorbents, and in particular activated carbon, are very challenging products to formulate because of their physicochemical properties such as low density, hydrophobicity, wetting properties, etc. Attempting to formulate activated charcoal for site-specific intestinal delivery of an oral dose is not possible using conventional direct compression because of the very low cohesive properties of activated charcoal. Even simple wet granulation and compression leads to tablets that exhibit poor adsorption properties and poor disintegration profile. Enzyme-based delivery systems have been proposed to overcome these problems. These systems are based on their degradation and subsequent release of their contents in the colon as a result of the action of colonic enzymes in a polymer that encapsulates the adsorbent. A representative system implements pectin beads specifically degraded by pectinolytic enzymes that are produced in the colon of many mammals by commensal flora bacteria (such as those described in WO2006/122835). However, this system has limitations such as low adsorbent content and difficulties in increasing the production of pectin pearls. Also, variability in the amount of pectinolytic enzymes present in the colon has led to variability in adsorbent delivery. Solid dosage forms, in single dosage form such as a tablet or in a multi-dispersed pellet formulation, have also been proposed, with excellent yield and adsorbent content (WO2007/132022). However, even though formulations can be prepared in a clear way, their disintegration properties and the adsorption efficiency of the released adsorbent can be improved in a more satisfactory way.
[0007] It would be advantageous to develop a formulation suitable for the delayed release of an adsorbent in the latter parts of the gastrointestinal tract while still preserving as much as possible the adsorption characteristics of the adsorbent. It would also be advantageous to produce a formulation with an improved adsorbent release profile, with a release of the adsorbent at a location and time in the gastrointestinal tract where no more antibiotic is absorbed. This would prevent any interaction of the adsorbent with the normal absorption process of antibiotics, or any other pharmaceutical product, when given simultaneously orally.
[0008] Such a formulation would be advantageous in removing residual antibiotics and/or their active metabolites from the intestinal tract while being able to be co-administered with a large number of antibiotics and to reduce unwanted antibiotic-associated side effects such as diarrhea, abdominal pain, and bacterial resistance to antibiotics. It would also be advantageous to have formulations that provide a specific release of an adsorbent in the lower gastrointestinal tract, specifically in the ileum, cecum, or colon.
[0009] Such a formulation would also be advantageous in reducing or eliminating the side effects of pharmaceutical agents or their metabolites in the ileum, cecum and colon. Such pharmaceutical agents are for example agents which are administered to treat a disease state, but which have side effects when they reach the lower part of the gastrointestinal tract, specifically in the ileum, cecum, or colon. Representative, non-limiting examples of such pharmaceutical agents include irinotecan and its metabolite SN-38, diacerein, Pancrelipase (such as Pancrease, Creon, Zenpep), Phosphodiesterase 4 inhibitors used in the treatment of chronic obstructive pulmonary disease such as Roflumilast or Cilomilast, or antifungal and anti-inflammatory drugs such as colchicine.
[0010] In addition, such a formulation would be advantageous in the treatment of disease states characterized by the accumulation of substances in the lower part of the gastrointestinal tract, this accumulation being responsible for the development of various pathological conditions. For example, the formulation may be useful for treating conditions such as, but not limited to, hepatic encephalopathy, irritable bowel syndrome, chronic renal failure, C. difficile associated diarrhea or antibiotic associated diarrhea. Representative substances that can be adsorbed by the formulation disclosed herein include, but are not limited to, ammonia, indoles, advanced glycation end products (AGEs) and certain bacterial toxins.
[0011] More generally, the formulation of the invention can be used in the treatment of a condition, pathological or not, that is caused, maintained and/or enhanced by the presence, or the presence in excess amounts, of certain substances in the lower part of the skin. gastrointestinal tract, specifically in the ileum, cecum, or colon.
[0012] The present invention provides such formulations and methods of preparation and use thereof. SUMMARY OF THE INVENTION
[0013] Formulations useful to deliver an adsorbent to the ileum, cecum or colon are provided. In one embodiment, a composition comprising a mixture of an adsorbent with carrageenan, preferably in the form of a pellet, is provided. In one aspect of this embodiment, the adsorbent is activated carbon, and in another aspect of this embodiment, the carrageenan is a capa-carrageenan. The amount of carrageenan is typically in the range of between 5% and 25%, more preferably between 10% and 20%, by weight of the mixture.
[0014] The composition comprising the mixture can be used to form a core. In one embodiment, the core is provided with a layer of a coating such that the adsorbent is released from the formulation in the lower part of the intestine, i.e., in the ileum, cecum and/or colon. Representative coatings that allow release to the desired part of the intestine include pH-dependent enter-soluble polymers, materials that are specifically degraded in the colonic environment by the action of microorganisms and/or the reductive environment found therein (e.g., azopolymers and disulfide polymers, polysaccharides, in particular amylose or pectin (for example pectin crosslinked with divalent cations such as calcium pectinate or zinc pectinate), chondroitin sulfate and guar gum). Representative pH-dependent enter-soluble polymers include cellulose acetate trimellitate (CAT), cellulose acetate phthalate (CAP), anionic copolymers based on methyl acrylate, methyl methacrylate and methacrylic acid, hydroxypropyl methylcellulose phthalate (HPMCP), succinate of hydroxypropylmethylcellulose acetate (HPMCAS), copolymers of methacrylic acid and ethyl acrylate, copolymer of methacrylic acid and ethyl acrylate, copolymers of methacrylic acid and methyl methacrylate (1:1 ratio), copolymers of methacrylic acid and methyl methacrylate (ratio 1:2), polyvinyl acetate phthalate (PVAP) and shellac resins. Particularly preferred polymers include shellac, anionic copolymers based on methyl acrylate, methyl methacrylate and methacrylic acid, and copolymers of methacrylic acid and methyl methacrylate (1:2 ratio). Ideally, the polymer dissolves at a pH of 6.0 and above, preferably 6.5 and above.
[0015] In another embodiment, another coating is provided between the core and the outer pH-dependent layer. The intermediate coating can be formed from a variety of polymers, including pH-dependent polymers, pH-independent water-soluble polymers, pH-independent insoluble polymers, and mixtures thereof.
[0016] Representative pH-dependent polymers include shellac polymers, anionic copolymers based on methyl acrylate, methyl methacrylate and methacrylic acid, methacrylic acid and ethyl acrylate copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), and hydroxypropylmethylcellulose acetate succinate (HPMCAS).
[0017] Representative pH-independent water soluble polymers include PVP or high molecular weight cellulose polymers such as hydroxypropylmethylcellulose (HPMC) or hydroxypropylcellulose (HPC).
[0018] Representative pH-independent insoluble polymers include polymers of ethylcellulose or copolymer of ethyl acrylate and methyl methacrylate.
[0019] In one aspect of this embodiment, the polymer layer that dissolves in a pH-independent manner includes at least one cellulose derivative selected from the group consisting of hydroxypropylcellulose or ethylcellulose. In another aspect of this embodiment, the polymer layer which dissolves in a pH-independent manner is made from a 1:9 to 9:1 mixture, preferably 2:8 to 3:7 of methacrylic acid and acrylate copolymer. of ethyl and copolymer of ethyl acrylate and methyl methacrylate.
The formulations can be used to eliminate or reduce side effects in the intestine, in particular the colon, of pharmaceutical agents. This is in particular aimed at eliminating or reducing the side effect of pharmaceutical agents which are administered as a treatment for a disorder, but which have side effects when they reach the ileum, cecum or colon. For example, the formulations can eliminate or reduce antibiotic-associated adverse effects of antibiotic agents, eliminate diarrhea, or eliminate the emergence of antibiotic resistance. The formulations can also eliminate a wide variety of pharmaceutical agents such as, but not limited to, those mentioned in the following detailed description. The formulations can be administered simultaneously with an antibiotic or other pharmaceutical agent.
The formulations can also eliminate or reduce the effects of bacterial or fungal toxins, such as mycotoxins, endotoxins or enterotoxins, or those produced by Clostridium difficile in the intestine and/or colon.
[0022] The formulations can also reduce flatulence, fecal odor, halitosis or food intolerance, particularly in a pet or a farm animal.
[0023] Methods of preparing the formulations are also disclosed.
[0024] Other purpose and applications will become evident in the following detailed description of the invention. BRIEF DESCRIPTION OF THE FIGURES
[0025] Figure 1: Adsorption kinetics of levofloxacin by NFAC (unformulated activated carbon) in simulated colonic fluid.
[0026] Figure 2: calibration of the microbiological assay for ciprofloxacin: relationship between concentration of ciprofloxacin Log10 and growth inhibition diameter.
[0027] Figure 3: Adsorption of ciprofloxacin on activated charcoal measured by microbiological assay.
[0028] Figure 4: Adsorption kinetics of levofloxacin by NFAC and DCP (unformulated coated pellets) in piglet cecal medium.
[0029] Figure 5: Desorption of levofloxacin from activated charcoal at various pHs. Desorption experiments were respectively carried out at pH 4.0 (A), 7.0 (B) and 10.0 (C). The mean of triplicate ± SD determinations is shown for each data point.
[0030] Figure 6: In vitro comparison of the adsorption kinetics of levofloxacin on NFAC and charcoal formulated in two ratios of charcoal/levofloxacin.
[0031] Figure 7: Adsorption of ciprofloxacin from BioDis profile on charcoal released from pellets coated with FS30D.
[0032] Figure 8: Comparison of coating thicknesses in BioDis profiles of ciprofloxacin adsorbed on charcoal released from pellets with a subcoat of L30D55/NE30D and a coating of FS30D.
[0033] Figure 9: Comparison of FS30D, Aqoat or Shellac coatings on the dissolution profile of different types of pellet in simulated ileal medium, pH 7.5 (as measured by ciprofloxacin adsorption).
[0034] Figure 10: Comparison of ethylcellulose coating thicknesses on the dissolution profile of pellets in simulated ileal medium, pH 7.5 (as measured by ciprofloxacin adsorption).
[0035] Figure 11A: Adsorption kinetics of irinotecan on activated carbon in simulated ileal media, pH 7.5.
[0036] Figure 11B: Adsorption kinetics of SN38 on activated carbon in 1 mM NaOH, pH 12.
[0037] Figure 11C: Adsorption kinetics of irinotecan on activated carbon in piglet cecal media reinforced with a mixture of SN38 and irinotecan.
[0038] Figure 11D: Adsorption kinetics of SN38 on unformulated coated pellets in piglet cecal media reinforced with a mixture of SN38 and irinotecan.
[0039] Figure 12: In vivo performance of targeted release activated charcoal in reducing the emergence of bacterial antibiotic resistance - study design.
[0040] Figure 13: Mean evolution of fecal concentrations of ciprofloxacin by group (n1 = 6, n2 = 11, n3 = 12). In this graph, we also plot for each group the 95% confidence interval defined as [mean-1.96*WEM; mean+1.96*SEM] where SEM is the standard error of the mean.
[0041] Figure 14: Mean evolution of ciprofloxacin plasma concentrations (ng/mL) by group (n2 = n3 = 12). In this graph, we also plot for each group the 95% confidence interval defined as [mean-1.96*WEM; mean+1.96*SEM] where SEM is the standard error of the mean.
[0042] Figure 15: Resistant bacterial counts: individual AUCciproD1-D8 mean corrected by treatment group represented by the dark area between the mean log10 curve of corrected ciprofloxacin-resistant bacterial counts from the reference value, and the X axis = 0 from Day 1 to Day 8 (n1 = 6, n2 =11, n3 = 12)
[0043] Figure 16: Creon adsorption kinetics on activated carbon in buffered medium, pH 7.5. DETAILED DESCRIPTION
[0044] The invention relates to a formulation including a carrageenan and an adsorbent. The formulation is suitable for the oral administration of an adsorbent and delivery of said adsorbent to the lower part of the intestine, i.e. the ileum, cecum and/or colon. In one embodiment, the carrageenan and adsorbent are present as a mixture, which mixture can be compressed to form a core (the core being further referred to herein as a particle or pellet).
[0045] The core can be coated with one or more layers of coating, and the coated or uncoated cores can be used to form a drug delivery vehicle, such as a tablet, capsule, pill, and the like.
[0046] The formulations of the invention are solid dosage forms useful for delivering an adsorbent to a desired part of the intestine, advantageously in the ileum, cecum or colon. Outer and/or intermediate coatings are in particular provided to minimize (preferably to fully prevent) the impact of the adsorbent on the normal absorption process of a therapeutic agent (eg an antibiotic) by the host organism when said therapeutic agent is administered orally together with the formulation according to the invention. Additionally or alternatively, the so-formulated adsorbent is prevented from non-specifically adsorbing material present in the gastrointestinal tract entirely to the terminal part of the small intestine. This results in the release of an unsaturated adsorbent, a completely or almost completely efficient adsorbent in the specific part of the intestine where its action is required.
[0047] Methods of preparing the formulations, and methods of treatment using the formulations, are also disclosed. The individual components of the formulations are described in detail below. ANTIBIOTICS
[0048] The term "antibiotic" denotes a substance that kills or inhibits the growth of microorganisms such as bacteria, fungi, or protozoa. Representative non-limiting antibiotics that can be adsorbed in accordance with the invention include Beta-lactams such as Amoxicillin, Ampicillin, Piperacillin, Cephalexin, Cefixime, Ceftazidime, Cefuroxime, Ceftriaxone, Cefotaxime, Ceftiofur, Cefdinir, Cefpodoxime, Cefquinoma, Cefquinoma, , Ceftarolime, Ceftiofur, Imipenem, Ertapenem, Doripenem, Meropenem and beta-lactmase inhibitors such as Clavulanate, Sulbactam or Tazobactam alone, or given in combination with other beta-lactam antibiotics; Tetracyclines such as Chlortetracycline, Oxytetracycline, Tetracycline, Doxycycline or Minocycline; Macrolides such as Tylosin, Erythromycin, Azithromycin, Clarithromycin, Roxithromycin, Telithromycin, Josamycin, Oleandomycin, Spiramycin, Clindamycin, Lincomycin, Quinupristin or Dalfopristin; Fluoroquinolones such as Nalidixic Acid, Ciprofloxacin, Norfloxacin, Ofloxacin, Levofloxacin, Moxifloxacin, Enrofloxacin, Sarafloxacin or Marbofloxacin; Sulfonamides such as Sulfamethoxazole, Sulfadiazine or Sulfathiazole; the dihydroflate reductase inhibitor Trimethoprim; the oxazolodinone antibiotic Linezolid:; or other antibiotics such as Florfenicol, Tiamulin or Tigecycline. ADSORBENTS
[0049] Examples of suitable adsorbents include activated carbon, clays including bentonite, kaolin, montmorillonite, attapulgite, halloysite, laponite, and the like, silica including colloidal silica (Ludox® AS-40 for example), mesoporous silica (MCM41), fumigated silica, zeolites and the like, talc, cholesteramine and the like, polystyrene sulfonates and the like, mono- and polysulfonated resins, and any other resins of interest such as those used for bacteriological testing such as BACTEC® resins. Among these adsorbents, it may be preferred to use pharmaceutical grade ones, such as activated carbon USP (Merck, France or other sources), kaolin (VWR, France), attapulgite (Lavollee, France), bentonite (Acros Organics, France), Talc USP (VWR, France).
The amount of adsorbent to produce a single dosage form may vary depending on the host being treated and the overall capacity and selectivity of the adsorbent for the antibiotic(s). The amount of adsorbent to produce a single dosage form will generally be that amount of the compound which produces a desired effect. The desired effect may be a therapeutic effect, for example a therapeutically significant decrease in the amount of antibiotic, metabolite thereof, bacterial toxin, or other compound that causes adverse effects in the terminal parts of the intestine, in particular the colon, as compared to the formulation is not administered.
The amount of adsorbent will range from about 1% to about 99% by weight of the total pellet, preferably from about 50% to about 95%, most preferably from about 65% to about 95%, in particular from about 80% to about 95% by weight of the core formulation.
[0052] In a particular embodiment, activated carbon is used. In one aspect of this embodiment, activated carbon preferably has a specific area above 1500 m2/g, preferably above 1600 m2/g and best above 1800 m2/g. CARRAGEENIN
[0053] Carrageenan is a naturally occurring family of linear sulfated polysaccharides that are extracted from red algae. It is a high molecular weight polysaccharide composed of galactose and 3,6-anhydrogalactose (3,6-AG) repeating units, both sulfated and unsulfated. The units are joined by alternating alpha 1-3 and beta 1-4 glycosidic bonds. Three basic types of carrageenan are commercially available, namely, kappa, iota, and lambda carrageenans, which differ by the number and position of the sulfate ester groups on the galactose units.
[0054] In one embodiment, carrageenan may be selected from kappa, iota and lamba carrageenans, and mixtures thereof. In one aspect of this embodiment, the adsorbent is mixed with kappa-carrageenan. In a particular embodiment, the mixture comprises activated carbon and kappa-carrageenan.
Preferably, the amount of carrageenan is between about 15% and about 25%, more preferably between about 10% and about 20%, by weight of the mixture of adsorbent and carrageenan. According to a specific embodiment of the invention, the amount of carrageenan is about 15% by weight of the mixture. For example, the mixture may contain 85% of an adsorbent and 15% of carrageenan, by weight of the total mixture. The possibility of formulating such large amounts of adsorbent with carrageenan was unexpected, and allows the delivery of large amounts of adsorbent, preferably activated charcoal, to the desired part of the intestine.
[0056] According to a particular embodiment of the invention, a mixture of activated carbon and carrageenan is provided in the weight ratio indicated above.
[0057] The core (or pellet) may be produced by any suitable means known to the qualified technician. In particular, granulation techniques are adapted to produce said core. For example, the core can be obtained by mixing the adsorbent and carrageenan in the ratio indicated above, adding a solvent such as water to proceed to wet granulation, followed by spheronization by extrusion or single-step pelletization. Any remaining water can be removed, for example, by drying using conventional techniques from the resulting pellets.
[0058] In one embodiment, the core, or pellet, of the invention has a weighted average particle size in the range 250 to 3000 µm, in particular 500 to 3000 µm. Several representative size ranges may be preferred. For example, the core size can be comprised between 500 and 1000 µm, or between 800 and 1600 µm. In the context of the present invention, the weighted average particle size is determined by sieving different size fractions, weighing the fractions and calculating the average particle size from the weights. The method is well known to a person skilled in the field of invention.
[0059] It was unexpectedly found that the mixture of an adsorbent, in particular activated carbon, and carrageenan has good formulation properties, including: - adequate flow characteristics that allow mass transport during the extrusion process, - self-propelling properties lubrication with limited adhesion to the material, - sufficient rigidity to maintain the shape of the extrudate, - firmness of the extrudate and enough fragility that allows for regular cutting of the extrudate, and - minimal plasticity, which allows good spheronization.
[0060] None of these advantageous properties have been reported in the prior art.
[0061] The invention thus also relates to a composition comprising a mixture of an adsorbent, preferably activated carbon, with carrageenan (in particular kappa-carrageenan). In another embodiment, said mixture is in the form of a particle (a compact mixture obtainable, for example, by an extrusion spheronization process), also called a pellet in the present application.
[0062] Those skilled in the art will recognize that the core composition may further include conventional excipients such as non-sticks, binders, fillers, diluents, flavors, colors, lubricants, glidants, preservatives, sorbents and sweeteners. The amounts of such excipients can vary, but will typically range from 0.1 to 50% by weight of the pellet. Naturally, the person skilled in the art will adapt these amounts so that the added excipient will not negatively impact the advantageous properties of the mixture of carrageenan and adsorbent. EXTERNAL ENTERIC COATING
[0063] The core of the formulation can be layered with a coating such that the drug is released from the formulation into a desired part of the intestine. Various systems are known to those skilled in the art for delivering an agent to different parts of the intestine. A comprehensive review of the different systems that can be implemented is provided in Pinto et al., Int J Pharm. August 16, 2010; 395(1-2):44-52.
[0064] In a particular embodiment of the invention, the core of the formulation may be layered with a coating such that the drug is released from the formulation in the lower part of the intestine, that is, in the ileum, cecum and/or colon. Any coating can be used which ensures that the formulation will not release the adsorbent until it is in the desired part of the intestine, ie the ileum, cecum or colon. The coating can be selected from coatings that are pH sensitive, redox sensitive or sensitive to particular enzymes or bacteria. Enteric coatings are well known to those skilled in the art (for example, reference is made to Chourasia MK and Jain SK, "Pharmaceutical methods to colon targeted drug delivery systems", J Pharm PharmaceutSci 6(1): 3366, 2003).
[0065] Preferred coating materials are those that are pH sensitive, i.e. pH-dependent enter-soluble polymers. As will be evident in the following parts of the application, the choice of pH-dependent enter-soluble polymer can be made by taking into account the pH profile of the gastrointestinal tract of the mammal that will be the recipient of the treatment (also referred to herein as the "host being treated ").
[0066] The term "enter-soluble polymer" denotes a polymer that is stable and does not dissolve in the stomach and upper parts of the gastrointestinal tract, but dissolves easily when it reaches the desired part of the intestine to release the active material contained therein. The solubility of a pH-dependent enter-soluble polymer depends on the acidity or alkalinity conditions found early on in the intestine.
[0067] In a particular embodiment, the pH-dependent enter-soluble polymer can be selected from cellulose acetate trimellitate (CAT), cellulose acetate phthalate (CAP) such as Aquateric®, anionic copolymers based on methyl acrylate , methyl methacrylate and methacrylic acid such as Eudragit® FS30D, Hydroxypropyl methylcellulose phthalate (HPMCP), Hydroxypropyl methylcellulose acetate succinate (HPMCAS) grades LF, LG, MF, MG or HF such as Aqoat®, copolymers of methacrylic acid and acrylate of ethyl such as Eudragit® L100-55, copolymer of methacrylic acid and ethyl acrylate such as Eudragit® L30D-55, copolymers of methacrylic acid and methyl methacrylate (1:1 ratio) such as Eudragit® L-100 and Eudragit ® L12.5, copolymers of methacrylic acid and methyl methacrylate (1:2 ratio) such as Eudragit®S-100 and Eudragit® S12.5, Polyvinyl acetate phthalate (PVAP) such as Sureteric® and Opadry ® e Shellac resins such as SSB® Aquago ld.
[0068] In a preferred embodiment, the pH-dependent enter-soluble polymer used in the outer layer dissolves at a pH equal to 6.0 and above. Even more preferably, it dissolves at a pH of 7.0 and above. In this context, the particular polymer can be selected from the group consisting of shellac such as SSB® Aquagold, anionic copolymers based on methyl acrylate, methyl methacrylate and methacrylic acid such as Eudragit® FS30D, copolymers of methacrylic acid and methacrylate of methyl (1:2 ratio) such as Eudragit®S-100 and Eudragit® S12.5, HPMCAS such as Aqoat® grades AS-MF, MG or HF or hydroxypropyl methylcellulose phthalate (HPMCP) such as grade HP-55 .
[0069] The Eudragit® copolymers referred to above are marketed by Evonik. Its composition is known to the qualified technician and can be found, in particular, in US 2008/0206350 (USSN 12/034,943).
[0070] The pH-dependent enter-soluble polymer is selected first for its ability to resist the acidic pH found in the upper gastrointestinal tract (GIT) of most mammals and second to meet the requirement to release the active agent in the lower part of the gastrointestinal tract (GIT). intestine, i.e. preferably the ileum, cecum or colon.
[0071] The person skilled in the art knows that in many mammals, the physiology of the GIT can vary so much in terms of pH, length, and transit time. Table 1 below represents the various physiological characteristics of some mammals. Table 1: Varied intestinal pH found in the intestine of different mammals


[0072] From KararliTT., Biopharm Drug Dispos. July 1995; 16(5):351-80. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Stevens C.E., and Hume, I.D. 1995. Comparative Physiology of the Vertebrate Digestive System. 2nd ed. New York: Cambridge University Press.
[0073] It can be seen from table 1 that most enterosoluble polymers will begin to dissolve in the upper part of the small intestine and, thanks to the thickness of the outer coating, the adsorbent will be released in the lower part of the intestine by the time dissolution is achieved .
[0074] The thickness of the coating can be adapted to finely adapt the release of the adsorbent in the desired part of the intestine. For example, the enter-soluble polymer layer can represent from 10% to 40% by weight of the total formulation weight. In a preferred embodiment, the amount of enter-soluble layer is at least 15% of the total weight of the formulation. In a preferred embodiment, the enter-soluble polymer layer represents from about 15% to about 35% by weight of the total formulation, even more preferably from about 15% to about 20%. In a particular embodiment, the enter-soluble polymer layer is present in the formulation in an amount of about 15% by weight of the total formulation.
[0075] The type and/or amount of enter-soluble polymer that can be used to coat the core of the invention can be selected using the Biodis dilution tester (USP III release apparatus) as provided in the examples.
[0076] The pH-dependent enter-soluble coating can also include various combinations of different pH-dependent enter-soluble polymers. Those skilled in the art are able to select such pH dependent polymer blends taking into account their general knowledge in this field. For example, as mentioned in the above-cited article by Chourasia and Jain, a combination of two methacrylic acid polymers such as Eudragit® L100-55 and Eudragit® S100 can be provided around the core of the invention.
[0077] In a particular embodiment of the invention, the outer coating contains Eudragit FS30D, or a mixture of Eudragit FS30D and Eudragit L30D-55 in a weight ratio comprised in particular between 99:1 to 80:20 (FS30D:L30D -55).
[0078] In a particular embodiment, the pH-dependent enter-soluble polymer is selected from - shellac, - anionic copolymers based on methyl acrylate, methyl methacrylate and methacrylic acid, - mixtures of methyl methacrylate and methacrylic acid such as Eudragit® FS30D and copolymer of methacrylic acid and ethyl acrylate such as Eudragit® L30D-55, in a ratio comprised between 99:1 and 80:20, and - copolymers of methacrylic acid and methyl methacrylate (weight ratio of 1:2).
[0079] In another particular embodiment, the formulation according to the invention comprises: - a core containing a mixture of activated carbon with carrageenan (preferably carrageenan cap), and - a layer of an anionic copolymer based on acrylate of methyl, methyl methacrylate and methacrylic acid such as Eudragit® FS30D. In another particular embodiment, the formulation according to the invention comprises: - a core containing a mixture of activated carbon with carrageenan (preferably kappa carrageenan), and - a layer of a mixture of methyl methacrylate and methacrylic acid such as Eudragit® FS30D and copolymer of methacrylic acid and ethyl acrylate such as Eudragit® L30D-55, in a ratio of between 99:1 and 80:20.
[0080] In another particular embodiment, the formulation according to the invention comprises - a core containing a mixture of activated carbon with carrageenan (preferably carrageenan cap), and - a shellac layer.
[0081] The outer enter-soluble layer can be applied over the core by any suitable means known to a person skilled in the art. For example, it can be applied using classical fluid bed technology where a water-based or solvent-based coating solution is applied by spray drying over the core pellet. When weight gain is achieved, the formulation can be dried and another coating applied. Multiple coats can thus be applied successively using spray drying technology.
[0082] In addition, the colonic region has a high presence of anaerobic microbial organisms providing reducing conditions. Thus the outer coating can suitably comprise a material which is sensitive to redox. Such coatings may comprise azopolymers which may for example consist of a random copolymer of styrene and hydroxyethyl methacrylate, crosslinked with divinylazobenzene synthesized by free radical polymerization, the azopolymer being broken down enzymatically and specifically in the colon, or disulfide polymers (see PCT/BE91 /00006).
[0083] Other materials providing colonic release are amylose, for example a coating composition can be prepared by mixing amylose-butan-1-ol complex (vitreous amylose) with an aqueous dispersion of Ethocel (Milojevic et al., Proc. Int. Symp. Contr. Rel. Bioact. Mater. 20, 288, 1993), or a coating formulation comprising an inner coating of glassy amylose and an outer coating of cellulose or acrylic polymer material (Allwood et al GB 9025373.3), pectin, a polysaccharide that is degraded by colonic bacterial enzymes (Ashford et al., Br Pharm. Conference, 1992, Abstract 13), cross-linked in a gel by divalent cations such as calcium (Rubenstein et al., Pharm. Res., 10 , 258, 1993) or zinc (El-Gibaly, Int. J. Pharmaceutics, 232, 199, 2002), chondroitin sulfate (Rubenstein et al., Pharm. Res. 9, 276, 1992) and resistant starches (Allwood et al. al., PCT WO 89/11269, 1989), dextran hydrogels (Hovgaard and Brondsted, 3rd Eur. Symp. Control. Drug Del., Abstract Book, 1994, 87) modified guar gum such as borax modified guar gum (Rubenstein and Gliko-Kabir, S.T.P. Pharma Sciences 5, 41-46, 1995), β-cyclodextrin (Siekeer al., I. J. Pharm. Biopharm. 40 (suppl), 335, 1994), saccharide-containing polymers whereby a polymeric construct is included comprising a biopolymer containing synthetic oligosaccharide including methacrylic polymers covalently linked to oligosaccharides such as cellobiose, lactulose, raffinose, and stachyose, or natural saccharide containing polymers including modified mucopolysaccharides such as cross-linked chondroitin sulfate; methacrylate-galactomannan (Lehmann and Dreher, Proc. Int. Symp. Control. Rel. Bioact. Mater.18, 331, 1991) and pH sensitive hydrogels (Kopecek et al., J. Control.Rel. 19, 121, 1992) ). Resistant starches, eg vitreous amylose, are friends that are not broken down by enzymes in the upper gastrointestinal tract but are degraded by enzymes in the colon. INTERMEDIATE COATING
[0084] According to a particular embodiment of the invention, the formulation described above comprises at least one other coating provided between the core and the outer enteric coating. These additional layer(s) (also referred to as "intermediate coating") are provided to further delay the release of the adsorbent when necessary. The intermediate coating is in particular provided to minimize (preferably to fully prevent) the impact of the adsorbent on the normal absorption process of a therapeutic agent (eg an antibiotic) by the host organism when said therapeutic agent is administered orally together with the formulation according to the invention. This embodiment is particularly suitable for the case where the therapeutic agent administered has a delayed absorption profile as a consequence of the time required to obtain maximum concentration of the agent in the blood (Tmax).
[0085] According to a particular embodiment, the intermediate coating is provided on the core of the invention, and another coating is applied with a pH-dependent enter-soluble polymer such as Eudragit™ FS30D (as explained above) or a mixture of Eudragit® FS30D and Eudragit® L30D-55, in a ratio comprised between 99:1 and 80:20. The pH-dependent enter-soluble polymer protects the core from the acidic environment found in the upper part of the gastrointestinal tract. Once the pH dependent polymer is dissolved, another delayed release of the adsorbent can be obtained due to the intermediate coating.
[0086] The intermediate coating may contain pH-dependent or pH-independent polymers.
[0087] Among the pH-dependent polymers that can be used as an intermediate coating, examples include those described above in the "enter-soluble outer layer" part, and in particular shellac-type polymers such as SSB® Aquagold, anionic copolymers based on methyl acrylate, methyl methacrylate and methacrylic acid such as Eudragit® FS30D, copolymer of methacrylic acid and ethyl acrylate such as Eudragit® L30D-55, HPMCAS such as Aqoat grades AS-MF, MG or HF or hydroxypropyl methylcellulose phthalate ( HPMCP) such as grade HP-55. In a particular embodiment, the intermediate coating can be a mixture of pH-dependent polymers such as Eudragit® FS30D and Eudragit® L30D-55, in a ratio comprised between 99:1 and 80:20
[0088] pH-independent polymers can be selected from slowly water-soluble polymers and water-insoluble polymers. Non-limiting examples of pH-independent water soluble polymers include Polyvinylpyrrolidone (PVP) and high molecular weight cellulose polymers such as hydroxypropylmethylcellulose (HPMC), hydroxypropyl cellulose (HPC). Other non-limiting examples of insoluble pH-independent polymers include polymers of ethylcellulose and copolymer of ethyl acrylate and methyl methacrylate (such as Eudragit® NE30D).
[0089] In a particular embodiment of the invention, the intermediate coating contains a mixture of polymers. In a first alternative, the polymer mixture comprises polymers of the same type. For example, the mixture may comprise a pH-dependent polymer with another pH-dependent polymer, a pH-independent soluble polymer with another pH-independent soluble polymer, or an insoluble pH-independent polymer with another pH-independent insoluble polymer . In another alternative, the polymer blend comprises polymers of different types. The mixture may comprise a pH-dependent polymer with a pH-independent polymer (soluble or insoluble in water), a pH-independent soluble polymer with an insoluble pH-independent polymer, or a pH-dependent polymer with a pH-independent soluble polymer and an insoluble, pH-independent polymer. For example, the intermediate coating may comprise blending a pH-dependent polymer with a pH-independent polymer, such as a blend of Eudragit® L30D55 with Eudragit® NE30D (for example, in a weight ratio of between about 1:9 and about 9:1, in particular between about 2:8 and about 3:7).
[0090] The weight ratio of coating and preferred coating component can be easily determined by those skilled in the art, for example, by evaluating the release profile of the dosage form as provided in the examples (eg, see Example 8).
[0091] For an orally given pharmaceutical agent, for example an antibiotic, which has a Tmax between about 1 and about 2 hours (such as ciprofloxacin), the core according to the invention may be coated with a single polymer pH dependent, such as an anionic copolymer based on methyl acrylate, methyl methacrylate and methacrylic acid (such as Eudragit® FS30D). Adsorbent release is achieved in vitro and in vivo (in particular in a human patient) after about 4 to 6 hours, which limits the interaction of the adsorbent with the normal absorption process of the antibiotic, or another pharmaceutical agent. The same type of formulations can be administered after parenteral administration of the antibiotic, where residual antibiotic is found in the gastrointestinal tract after excretion from the biliary or intestinal membrane. In this case, there is no risk of interaction of the adsorbent with the antibiotic absorption process.
[0092] In the case where pharmaceutical agents with delayed absorption (Tmax above 2 hours), and in particular antibiotics such as third-generation cephalosporins, are given orally concurrently with the adsorbent material formulated in a delayed delivery system such as those described above, it may be preferable to further delay the release of the adsorbent. This can be achieved, for example, by primarily coating the core with between about 1 and about 3% ethylcellulose (w/w of the total formulation), preferably 1.5 to 2.5% (w/w of the formulation total), more preferably with 2% ethylcellulose or a mixture of Eudragit® L30D-55 with Eudragit® NE30D (between 10 and 40%, preferably between 15 and 35% w/w of the total formulation) further coated with at least 15% (w/w of total formulation) of Eudragit® FS30D.
[0093] In a particular embodiment, the intermediate coating is selected so as to obtain a delay of about 20 minutes to about 2 hours in the release of the adsorbent, as measured by the in vitro test such as with a BioDis dissolution tester (USP III release apparatus). In the system, the dosage form is successively placed in glass tubes filled with approximately 200 ml of dissolution medium with a composition producing pH, buffering capacity and osmolarity corresponding to the different sections of the gastrointestinal tract, as described by Jantratid et al. in Pharm. Res. 25 (2008), 1663-1676. This allows for a good simulation of the release in vivo before testing in mammals. pH, fed vs fasted state, and various other physiological conditions can be tested. Using the BioDis system, it is possible for those skilled in the art to finely tailor the formulation to obtain a desired predetermined delayed release.
[0094] According to the above, a particular embodiment of the invention relates to a formulation comprising: - a core comprising a mixture of an adsorbent with carrageenan, - an outer layer of a pH-dependent enter-soluble polymer, and - an intermediate coating provided between the core and the outer layer.
[0095] In a particular embodiment, the invention relates to a formulation comprising: - a core comprising a mixture of activated carbon with carrageenan (preferably capa-carrageenan), - an intermediate coating selected from the group consisting of HPMC, ethylcellulose and a blend of methacrylic acid and ethyl acrylate copolymer such as Eudragit® L30D-55 and ethyl acrylate and methyl methacrylate copolymer such as Eudragit® NE30D (for example in a mixing ratio of 1:9 to 9:1 , preferably from 2:8 to 3:7), and - an outer layer of an anionic copolymer based on methyl acrylate, methyl methacrylate and methacrylic acid, such as Eudragit® FS30D.
[0096] In another particular embodiment, the formulation of the invention comprises: - a core comprising a mixture of activated carbon with carrageenan (preferably capa-carrageenan), - an intermediate coating of 1 to 3% ethylcellulose, preferably a coating of 1.5 to 2.5% ethylcellulose, most preferably an intermediate coating of 2% ethylcellulose (w/w of total formulation), and - a 15% outer layer (w/w of total formulation) of a anionic copolymer based on methyl acrylate, methyl methacrylate and methacrylic acid such as Eudragit® FS30D.
[0097] In another particular embodiment, the formulation of the invention comprises: - a core comprising a mixture of activated carbon with carrageenan (preferably capa-carrageenan), - an intermediate coating at 15 to 35% (w/w of the formulation total) manufactured from a 2:8 to 3:7 blend of methacrylic acid and ethyl acrylate copolymer (such as Eudragit® L30D-55) and ethyl acrylate and methyl methacrylate copolymer (such as Eudragit® NE30D), and - an outer layer at 15% (w/w of the total formulation) of an anionic copolymer based on methyl acrylate, methyl methacrylate and methacrylic acid, such as Eudragit® FS30D.
[0098] In another particular embodiment, the formulation of the invention comprises: - a core comprising a mixture of activated carbon with carrageenan (preferably capa-carrageenan), - an intermediate coating of 1 to 3% ethylcellulose, preferably a coating of 1.5 to 2.5% ethylcellulose, most preferably an intermediate coating of 2% ethylcellulose (w/w of total formulation), and - an outer layer of 15% to 35% (w/w of total formulation) ) of a mixture of methyl methacrylate and methacrylic acid such as Eudragit® FS30D and copolymer of methacrylic acid and ethyl acrylate such as Eudragit® L30D-55, in a ratio comprised between 99:1 and 80:20.
[0099] In another particular embodiment, the formulation of the invention comprises: - a core comprising a mixture of activated carbon with carrageenan (preferably capa-carrageenan), - an intermediate coating at 15 to 35% (w/w of the formulation total) manufactured from a 2:8 to 3:7 blend of methacrylic acid and ethyl acrylate copolymer (such as Eudragit® L30D-55) and ethyl acrylate and methyl methacrylate copolymer (such as Eudragit® NE30D), and - an outer layer 15% to 35% (w/w of the total formulation) of a mixture of methyl methacrylate and methacrylic acid such as Eudragit® FS30D and copolymer of methacrylic acid and ethyl acrylate such as Eudragit® L30D-55 , in a ratio between 99:1 and 80:20. DOSAGE FORMS
[0100] In another aspect, the present invention provides pharmaceutically acceptable dosage forms comprising a therapeutically effective amount of one or more of the adsorbents described above, formulated together with carrageenan and one or more pharmaceutically acceptable additives. As described in detail below, the dosage forms of the invention may be specially formulated for administration in solid form.
[0101] The phrase "therapeutically effective amount" as used herein means that amount of one or more of the above-described compounds, material, or formulation comprising one or more of the above-described compounds that is effective to produce some desired therapeutic effect.
[0102] The phrase "pharmaceutically acceptable" is used herein to refer to those compounds, materials, formulations, and/or dosage forms that are, within the scope of correct medical judgment, suitable for use in contact with the tissues of beings. humans and animals without excessive toxicity, irritation, allergic response, or other problem or complication, consistent with a benefit/risk ratio.
[0103] The phrase "pharmaceutically acceptable additive" as used herein means a pharmaceutically acceptable material, formulation or vehicle, such as a solid filler, diluent, excipient involved in carrying or transporting the object compound from an organ, or portion of the body, to another organ, or portion of the body. Each additive must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the patient.
[0104] Dosage forms that contain multiple units, such as pellets individually coated with enter-soluble polymers such as the one described above, may be preferred in order to improve the in vivo dispersion of the activated carbon. Such pellets have more practical flexibility because the coating can be directly obtained on their surface, for example, using a fluid bed system.
[0105] Wetting agents, emulsifiers and lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants may also be present in the dosage form.
[0106] Dosage forms of the present invention include those suitable for oral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
[0107] Dosage forms of the invention suitable for oral administration may be in the form of capsules, tablets, sachets, each containing a predetermined amount of the adsorbent formulation.
[0108] A tablet can be manufactured by compression or molding, optionally with one or more accessory ingredients. Compressed tablets can be prepared using binder (eg, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (eg, sodium starch glycolate, cross-linked sodium carboxymethyl cellulose or polysaccharide), surface-active agent or dispersant. Molded tablets can be manufactured by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent such as water.
[0109] The solid dosage forms described above can be combined into a final dosage form comprising single or multiple units. Examples of multiple units include multi-layer tablets, capsules containing tablets, pellets, granules, etc.
[0110] The core of the invention may be coated with an outer layer, and optionally an intermediate coating as provided above. The coated formulation (coated with an outer enteric coating, and whether or not comprising an intermediate coating) or uncoated core can be further combined into a single drug dosage form, such as a tablet, capsule, and the like, which can be coated. further with a coating material for effective delayed release including, but not limited to, cellulosic polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, sodium carboxymethyl cellulose, copolymers such as polyvinyl pyrrolidone; hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate and acrylic acid polymers and copolymers, preferably formed from acrylic acid, methacrylic acid, methyl acrylate, ethyl acrylate, methacrylate of methyl and/or ethyl methacrylate, and other methacrylic resins which are commercially available under the trade name Eudragit®. (Rohm Pharma; Westerstadt, Germany), including Eudragit® L30D-55 and L100-55 (soluble in pH 5.5 and above), Eudragit® L-100 (soluble in pH 6.0 and above), Eudragit® S ( soluble at pH 7.0 and above as a result of a higher degree of esterification), and Eudragit FS30D an anionic copolymer of methacrylic acid, methyl acrylate and methyl methacrylate; ethyl cellulose, cellulose acetate; Eudragit® NE, RL and RS (water-insoluble polymers having different degrees of permeability and expandability) vinyl acetate, vinyl acetate phthalate, vinyl acetate crotonic acid copolymer, and ethylene-vinyl acetate copolymer; vinyl polymers and; Enzymatically degradable polymers such as azo, pectin, chitosan, amylose and guar gum polymers; zein and shellac.
[0111] Preferred coating weights for particular coating materials can be easily determined by those skilled in the art by evaluating individual release profiles for tablets, pellets and granules prepared with different amounts of various coating materials.
[0112] That is, the combination of materials, method and form of application that produce the desired release characteristics.
[0113] The coating formulation can include conventional additives such as plasticizers, pigments, dyes, stabilizing agents, glidants, etc. A plasticizer is usually present to reduce the brittleness of the coating, and will generally represent about 5% by weight to 50% by weight relative to the dry weight of the polymer. Examples of typical plasticizers include polyethylene glycol, propylene glycol, triacetin, dimethyl phthalate, diethyl phthalate, dibutyl phthalate, dibutyl sebacate, triethyl citrate, tributyl citrate, triethyl acetyl citrate, castor oil and acetylated monoglycerides. A stabilizing agent is preferably used to stabilize particles in the dispersion. Typical stabilizing agents are nonionic emulsifiers such as sorbitan esters, polysorbates and polyvinylpyrrolidone. Slippers are recommended to reduce adhesion effects during film formation and drying, and will generally represent approximately 0% by weight to 100% by weight of the weight of polymer in the coating solution. An effective glidant is talc. Other glidants such as magnesium stearate and glycerol monostearates can also be used. Pigments such as titanium dioxide can also be used. Small amounts of an anti-foaming agent, such as a silicone (eg, simethicone), can also be added to the coating formulation.
These dosage forms can be administered to humans and animals for therapy by any suitable route of administration.
[0115] Actual dosage levels of the adsorbent in the dosage form of this invention may be varied in order to obtain effective removal of any residual antibiotic or other pharmaceutical agents or toxin in the intestinal tract, for a particular patient, formulation, and mode of administration , without being toxic to the patient.
[0116] The selected dosage level will depend on a variety of factors including the activity of the particular compound of the present invention employed, the time of administration, the rate of excretion or metabolism of the particular compound being employed, the duration of treatment, other medications, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and similar factors well known in the medical art.
[0117] A physician or veterinarian having common skill in the art can easily determine and prescribe the effective amount of the pharmaceutical formulation required. For example, the physician or veterinarian may start doses of the compounds of the invention employed in the pharmaceutical formulation at levels lower than that necessary in order to obtain the desired therapeutic effect and gradually increase the dosage until the desired effect is obtained.
In general, a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest effective dose to produce a therapeutic effect. Such an effective dose will generally depend on the factors described above.
[0119] If desired, the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
[0120] As already mentioned, the formulation according to the invention can be used in a method to eliminate the adverse effects of therapeutic agents, in particular, but not only, of antibiotics. According to a particular embodiment of this method, the formulation of the invention and the therapeutic agent are administered simultaneously. As such the amount of adsorbent can be adapted to the amount of therapeutic agent administered to the patient in need thereof. In this case, the weight ratio of adsorbent to antibiotic agent may be above 1, more preferably above 2, even more preferably above 3, and most preferably above 9.
[0121] The term "treatment" is intended to also include prophylaxis, therapy, and cure.
[0122] The individual receiving this treatment is any animal in need, including primates, in particular humans, and other mammals such as horses, cattle, swine and sheep; poultry and pets in general can also be recipients of such a treatment.
[0123] The administration of the formulation according to the invention to an animal is preferably carried out by including it in the animal's feed. This is preferably done by preparing a suitable feed premix containing the formulations according to the invention in an effective amount and incorporating the premix into the complete feed. Accordingly, the present invention also relates to an animal feed premix comprising feed and formulations as described above. The invention also relates to an animal feed comprising the formulations according to the invention. APPLICATIONS THERAPEUTIC APPLICATIONS:
[0124] The formulations according to the invention can be used to treat conditions and disorders for which intestinal delivery of adsorbents is appropriate. Consequently, the invention also relates to a formulation as described above, for use as a medicine.
[0125] The formulation according to the invention can be used to adsorb and therefore remove from the intestine any drug, metabolite or prodrug thereof, or toxin. This can be done after oral or parenteral administration of an active drug, which can be useful to limit or lessen adverse effects in the individual being treated when they reach the large intestine and/or colon.
[0126] As such, the present invention relates to the formulation as described above, for use in a method of eliminating drugs in the intestinal tract before they reach the colon or as they reach the colon, preferably before they reach the cecum or as they reach the cecum and proximal colon.
[0127] The invention further provides a method of eliminating drugs in the intestinal tract before they reach the colon or as they reach the colon, preferably before they reach the cecum or as they reach the cecum and proximal colon, comprising administering to a patient in need thereof a formulation according to the invention.
[0128] In addition, the invention provides a formulation as described above, for use in a method to reduce or eliminate the side effect(s) of a drug in the intestinal tract, wherein the formulation eliminates the drug before it reaches the colon or as it reaches the colon, preferably before it reaches the cecum or as it reaches the cecum and proximal colon.
[0129] The terms "drug", "therapeutic agent" and "pharmaceutical agent", and terms derived therefrom, are used interchangeably herein and refer to a compound that provides a desired biological or pharmacological effect when administered to a human or animal.
[0130] Conditions and disorders that can be treated with the formulation according to the invention may be those that result from exposure of the colon to antibiotics, such as the development of antibiotic resistance, development associated with antibiotic treatment of C. difficile ( or other pathogenic bacteria), fungal infections associated with antibiotic treatment, or diarrhea associated with antibiotic treatment. The adsorbent will adsorb residual antibiotics, and formulations according to the invention can be administered in a therapeutically effective dosage to a patient who has been, is being, or will be administered with an antibiotic. Any antibiotic that can be adsorbed in/on the adsorbent can be inactivated and has no antibiotic activity once completely adsorbed. Representative examples of antibiotic classes that can be adsorbed include beta-lactams, cyclins, macrolides, quinolones, aminoglycosides, glycopeptides, sulfonamides, phenicols, furans, polypeptides, oxazolidones, and antibiotics such as fosfomycin, rifampin, and the like.
[0131] The invention thus also relates to a formulation as described above, for use in a method of eliminating residual antibiotics in the intestinal tract, preferably before they reach the colon or as they reach the colon. Most preferably, the formulation is used in a method to eliminate residual antibiotics in the intestinal tract, preferably before they reach the cecum or as they reach the cecum and proximal colon. According to the invention, the adsorbent is preferably released between the part of the intestine where antibiotics are absorbed (duodenum and jejunum) and where their deleterious effect on commensal bacteria occurs (cecum and colon). The invention further relates to a method for eliminating residual antibiotics in the intestinal tract, preferably before they reach the colon or as they reach the colon, most preferably before they reach the cecum or as they reach the cecum and proximal colon comprising administering to a subject in need thereof an effective amount of the formulation of the invention.
[0132] The invention further relates to a formulation as described above, for use in a method to eliminate the adverse effects of antibiotic agents in the intestinal tract, in particular to eliminate the development of antibiotic resistance, development associated with antibiotic treatment of C. difficile (or other pathogenic bacteria), fungal infections associated with antibiotic treatment, or diarrhea associated with antibiotic treatment. The invention further relates to a method of eliminating the adverse effects of antibiotic agents on the intestinal tract comprising administering to a subject in need thereof an effective amount of the formulation of the invention.
[0133] In another embodiment, the formulation of the invention is administered to a patient suffering from a disorder treated with pharmaceutical agents that have side effects when they reach the lower intestine, in particular when they reach the colon. As developed below, Irinotecan is a representative compound having such behavior.
[0134] In particular embodiments, the formulation is administered to a patient suffering from a disorder treated with pharmaceutical agents that bind to relevant receptors in the patient's body except in the colon to treat the disorder, but which, when bound to receptors in the colon, result in side effects. For example, the colon includes cholinergic and serotonin receptors, which are also present in the central nervous system. Treatment with agents that bind to cholinergic receptors can result in side effects if the compounds bind to receptors in the colon. Co-administration of the formulation of the invention with agents that bind to such receptors can minimize or eliminate these side effects.
[0135] The invention thus also relates to a formulation as described above, for use in a method for eliminating side effects in the intestine, in particular the colon, of pharmaceutical agents administered as a treatment for a disorder, but which have effects collateral when they reach the ileum, cecum, or colon. The present invention can alleviate or eliminate these side effects. The invention further relates to a method for eliminating side effects in the intestine, in particular the colon, of pharmaceutical agents, in particular pharmaceutical agents administered as a treatment for a disorder, but which have side effects when they reach the ileum, the cecum or colon, comprising administering to a subject in need thereof an effective amount of the formulation of the invention. In particular, the present invention can be used to alleviate or eliminate inflammation and/or diarrhea induced by treatment with a pharmaceutical agent.
[0136] Irinotecan is a non-limiting, illustrative example of a pharmaceutical agent administered as a treatment for a disorder, but which has side effects when it, and/or its metabolites, reach the ileum, cecum, or colon. A particular embodiment of the invention provides a formulation for eliminating or reducing Irinotecan-induced diarrhea, in particular Irinotecan-induced late-onset diarrhea.
[0137] Irinotecan (also known as CPT-11), a semi-synthetic analogue of the natural alkaloid camptothecin, is a soluble prodrug of 7-ethyl-10-hydroxycamptothecin (SN-38) which is a topoisomerase I inhibitor that has activity antineoplastic 1000 times more potent than the in vitro prodrug form. Irinotecan was most particularly approved by the FDA for metastatic colorectal cancer in 1998. It is primarily used as a first-line combination regimen or as a single agent after 5-fluorouracil (5-FU)-based therapy has failed. However, it has been found that late-onset diarrhea is a major dose-limiting toxicity of irinotecan. The accumulation of SN-38 in the intestine is the main cause of irinotecan-induced late-stage diarrhea.
[0138] More commonly, diarrhea often develops as a side effect during clinical treatment with chemotherapeutic agents. This adverse effect is most commonly associated with chemotherapeutic agents such as 5-fluorouracil, cisplatin or irinotecan. In particular, late-onset diarrhea due to administration of Irinotecan may be persistent, may lead to dehydration and electrolyte disturbance, and may be, in some cases, sufficiently serious (grade 3 or 4 diarrhea) that administration of Irinotecan should be modified, discontinued or discontinued. Diarrhea is a troublesome symptom for patients, and because it can lead to reductions in irinotecan doses or the frequency of irinotecan administration, diarrhea can compromise the therapeutic effectiveness of irinotecan which is highly dependent on the dose administered.
[0139] A sign of the importance and frequency of this side effect is the fact that a protocol for treatment by loperamide, in case diarrhea occurs, is still indicated on the labeling of Irinotecan. In fact, in humans, intensive and immediate administration of loperamide (an agent that shows intestinal motility and affects the movement of water and electrolyte through the intestine) is used to reduce or control diarrhea once the diarrhea has started. However, loperamide has side effects on its own, such as inducing intestinal occlusion (Hanauer, SB, Rev Gastroenterol Disord. 8 (2008), 15-20).
[0140] Prevention of Irinotecan-induced diarrhea with activated charcoal has previously been proposed (Michael et al., Journal of Clinical Oncology, Vol. 22, No. 21, 1 November 2004). However, treatment consisted of oral administration of unformulated activated charcoal. This raises at least two problems, both related to the non-specific nature of this adsorbent. One of these problems is the likely saturation of activated charcoal by digestive material as it progresses through the gastrointestinal tract. It would be preferable to provide the terminal parts of the intestine with a maximally active adsorbent so as to obtain a strong adsorption of Irinotecan and/or its metabolites at the site where they evoke their unwanted effects. The second problem is related to the fact that irinotecan is often administered within a multiple drug treatment regimen, which may comprise orally administered drugs. In particular, Irinotecan can be administered in combination with 5-fluorouracil and leucovorin; other medications may be added, as needed for various reasons, to the treatment. Co-administration of charcoal not formulated in this context is undesirable as the adsorbent may adsorb the co-administered drug(s) and thus prevent them from evoking the desired effects they have been used for.
[0141] The present invention is advantageous in that it allows to eliminate or reduce the adverse effects of Irinotecan, in particular diarrhea induced by Irinotecan (most particularly late onset diarrhea induced by Irinotecan) without evoking other adverse effects or toxicity. Furthermore, thanks to the present invention, Irinotecan can be used at its most effective therapeutic dose as no change in dosage regimen is necessary because of the elimination of the adverse effects of Irinotecan. In preventing diarrhea symptoms in patients receiving Irinotecan therapy, the formulation of the present invention has the potential to reduce the incidence, severity, and/or duration of diarrhea, improve the patient's quality of life, prevent diarrhea-related hospitalization, and/or prevent irinotecan dose reduction, interruption or discontinuation of treatment.
[0142] The method of the invention also provides elimination or reduction of Irinotecan metabolites, in particular SN-38, and the elimination or reduction of the adverse effect of such Irinotecan metabolites.
[0143] The person skilled in the art will recognize that these advantages are also provided for therapy with molecules other than irinotecan, which evoke adverse effects, in particular molecules that induce diarrhea, when they reach the lower part of the gastrointestinal tract. Such molecules may be other camptothecin analogues and derivatives, such as Topotecan, and other drugs used in cancer chemotherapy.
[0144] Colchicine, a medicine used for the treatment of pain and gout and arthritis is another representative example of a pharmaceutical agent whose elimination according to the invention would be advantageous.
[0145] It is also known that gastrointestinal problems are commonly reported because of adverse drug reactions with blood pressure measurements (calcium channel blockers), pain medications (especially narcotics), antidepressants, antacids containing aluminum and calcium, antiparkinsonian medications , antispasmodics, diuretics, and anticonvulsants, and that many classes of medication are associated with constipation. Constipation often persists, and patients discontinue treatment because the side effect is bothersome. Medications such as risperidone may be associated with colonic disorders such as megacolon (Lim et al, Singapore Med J 2002, Vol 43(10): 530-532). The formulation of the invention can be administered to a patient in need thereof to treat these problems.
[0146] Thus, in a particular embodiment, the invention relates to a formulation as described above, for use in a method to eliminate side effects in the intestine, in particular in the colon, of a therapeutic agent, for example of a chemotherapeutic agent, in particular irinotecan and derivatives thereof (in particular its metabolite SN-38). The invention further relates to a method for eliminating side effects in the intestine, in particular in the colon, of a therapeutic agent, for example of a chemotherapeutic agent, in particular of Irinotecan and derivatives thereof (in particular its metabolite SN-38) when it reaches the ileum, cecum or colon, comprising administering to a subject in need thereof an effective amount of the formulation of the invention.
[0147] The invention further relates to a method for treating cancer (in particular metastatic colorectal cancer) with a chemotherapeutic agent, in particular with Irinotecan, comprising administering to a patient in need thereof - an effective amount of the chemotherapeutic agent, and - an effective amount of the formulation according to the invention.
[0148] The invention also relates to a method for reducing or eliminating the need to decrease the dose, interrupt or discontinue the use of a therapeutic agent, for example a chemotherapeutic agent, in particular Irinotecan, comprising administering a formulation in accordance with with the invention to a patient in need of therapy by said therapeutic agent.
[0149] The formulation according to the invention can be administered before, with or after the administration of the therapeutic agent that is intended to be eliminated from the lower parts of the gastrointestinal tract according to the invention. Preferably, the formulation according to the invention is administered before, or together with, the therapeutic agent. For example, the individual is simultaneously taking an antibiotic (or another therapeutic agent, for example a chemotherapeutic agent such as Irinotecan, etc.) and a formulation according to the invention.
[0150] Thus, for example, the administration of the therapeutic agent and the formulation according to the invention can be simultaneous or sequential (the formulation according to the invention being administered before or after the administration of the therapeutic agent), as a single dose or repeated several times a day, for a day or several days. Administration of the formulation of the present invention may begin prior to administration of the therapeutic agent, and be continued after said administration of the therapeutic agent.
[0151] In addition, the formulation of the invention can also be administered before or after, preferably before, the onset of the adverse effect to be eliminated. In an illustrative embodiment, the formulation of the invention is administered before the patient is treated with a therapeutic diarrhea-inducing agent such as irinotecan, colchicine, or others. The formulation of the invention may be administered once or at multiple times, for example every four or six hours one or two days before, as well as after administration of the therapeutic agent, for one or several days.
[0152] In a particularly preferred embodiment, in the context of treating a patient with Irinotecan, the formulation of the invention is administered prior to administering Irinotecan to the patient, for example one or two days before, once or several times per day (for example at every meal), and administration of the formulation is continued on the day of administration of Irinotecan and at least 4 days after administration of Irinotecan, preferably several times a day. Ideally, treatment is continued for 4 to 10 days, preferably 7 days after the administration of Irinotecan to make sure all remaining traces of Irinotecan or its metabolites are cleared from the patient's intestine.
[0153] The invention also relates to a kit comprising at least a first formulation comprising a therapeutic agent whose presence is undesired in the lower parts of the intestine, and a formulation containing an adsorbent as described above. The invention further relates to a kit according to the invention, for use in one of the methods described above, comprising administering the kit formulations to a subject in need thereof. The formulations are administered sequentially (one before the other) or simultaneously, preferably simultaneously.
[0154] The invention further relates to a method for the treatment of a disease state in an individual in need thereof, comprising: - administering to the individual a pharmaceutical agent useful for the treatment of the disease, in particular an antibiotic (or any another pharmaceutical agent having side effects when it reaches the lower part of the intestine, as described above), and - administering to the same individual, sequentially (before or after administration of the pharmaceutical agent) or simultaneously the formulation according to the invention, to eliminate or reduce the amount of the pharmaceutical agent in the lower intestine (ie, the ileum, cecum or colon).
[0155] Representative, non-limiting examples of pharmaceutical agents that can be used in the treatment of a disease state along with the formulation of the invention include anti-neoplastic agents, for example topoisomerase I inhibitors such as camptothecin derivatives like irinotecan or topotecan, anti-cancer compounds -inflammatory or interleukin-1 inhibitors such as diacerein, pancrelipase (such as Pancrease, Creon, Zenpep), selective phosphodiesterase-4 inhibitors used for the treatment of Chronic Obstructive Pulmonary Disease (COPD) such as roflumilast or cilomilast, and compounds having antimycotic activities such as colchicine.
[0156] As described above, the content of the formulation according to the invention can be adapted to the absorption profile of most types of therapeutic agents, and in particular to most classes of antibiotic agents. As an effect, the adsorbent delivery is more reliable and consistent to obtain no interaction with the normal therapeutic agent absorption process. Consequently, and as provided above, the delivery of the adsorbent can be delayed in such a way as to provide release at a predetermined time after the therapeutic agent, for example an antibiotic, is completely absorbed to have its therapeutic effect. This is achieved through specific coatings, providing both protection in the upper part of the intestinal tract and portrayed release of the efficient adsorbent. This provides a greater and very innovative advantage over the general and specific methods mentioned above.
[0157] The administration sequence can also be adapted by the person skilled in the art. For example, a pharmaceutical treatment may comprise administration of the pharmaceutical agent by routes other than the oral route. For example, a pharmaceutical agent can be administered via a parenteral route, such as by injection (e.g., intravenous, intraarterial, intrathecal, intramuscular injection). In this case, the person skilled in the art will adapt the administration time of the formulation of the invention according to his knowledge of the excretion time of the pharmaceutical agent in the gastrointestinal tract.
[0158] The formulation can also be administered to a patient suffering from the effects of bacterial or fungal toxins in the colon. Examples of such toxins include mycotoxins, endotoxins or enterotoxins such as those produced by Clostridium difficile (believed to be a leading cause of post-antibiotic diarrhea worldwide). In this embodiment, the adsorbents are administered in a therapeutically effective dosage to adsorb the toxins.
[0159] The invention thus also relates to a formulation as described above, for use in a method for eliminating the effects of bacterial or fungal toxins in the colon. The invention further relates to a method of eliminating the effects of bacterial or fungal toxins in the colon, comprising administering to a subject in need thereof an effective amount of the formulation of the invention.
[0160] In addition, the invention also relates to a formulation as described above, for use in a method for the treatment of disease states characterized by the accumulation of substances in the lower part of the gastrointestinal tract, this accumulation being responsible for the development of various pathological conditions. For example, the formulation may be useful for treating conditions such as, but not limited to, hepatic encephalopathy, irritable bowel syndrome, chronic renal failure, C. difficile associated diarrhea or antibiotic associated diarrhea. Representative substances that can be adsorbed by the formulation disclosed herein include, but are not limited to, ammonia, indoles, advanced glycation end products (AGEs) and certain bacterial toxins.
[0161] The formulation of the invention can be administered to a patient suffering from Chronic Kidney Failure (CKD). Advanced glycation end products (AGEs), phenols (eg p-cresyl sulphate) and indoles (eg indoxyl sulphate) are representative toxins generated or introduced into the body via the intestine that may be involved in CKD. Accordingly, in a particular embodiment, the invention relates to the formulation as defined above for use in a method for the treatment of CKD. The invention more specifically relates to a formulation as described above, for use in a method for eliminating toxins involved in the generation of uremic retention solutes. The invention further relates to a method of eliminating the effects of toxins involved in the generation of uremic retention solutes, comprising administering to an individual in need thereof an effective amount of the formulation of the invention. More specifically, the invention relates to eliminating or reducing the amount of AGEs, phenols (eg p-cresyl sulphate) and/or indoles (eg indoxyl sulphate) in the lower part of the intestine (i.e. the ileum, the cecum or colon).
[0162] The formulation of the invention can be further administered to a patient suffering from Inflammatory Bowel Disease (IBD), in particular from ulcerative colitis or Crohn's disease. Thanks to the formulation of the invention, it is now possible to induce or re-establish immune tolerance by recomposing the commensal microflora in the intestine adsorbing excess non-specific mucous bacteria or aggressive metabolites and mediators that accumulate in the intestinal mucosa such as nitric oxide, oxygen radicals , prostaglandins, leukotrienes, histamine, proteases, and matrix metalloproteinases. The invention thus relates to the formulation as described above, for use in a method for inducing or re-establishing immunological tolerance in a patient suffering from an IBD, in particular from ulcerative colitis or Crohn's disease. The invention therefore also relates to a method for the treatment of an IBD, in particular ulcerative colitis or Crohn's disease, comprising administering to a patient in need thereof a formulation according to the invention. The invention further relates to a formulation as described above for use in a method for eliminating or reducing the amount of excess non-specific mucous bacteria or aggressive metabolites and mediators that accumulate in the intestinal mucosa such as nitric oxide, oxygen radicals, prostaglandins, leukotrienes, histamine, proteases or matrix metalloproteinases.
[0163] The formulation according to the invention can also be used to treat Hepatic Encephalopathy (HE). A key role is considered to be played in this disorder by circulating intestinal-derived toxins of nitrogenous compounds, notably ammonia. The formulation according to the invention for example can be used to adsorb ammonia produced by bacteria in the intestine of a patient in need thereof. As such, the invention relates to a formulation as described above, for the elimination or reduction of nitrogenous compounds, notably ammonia, in the intestine of a subject in need thereof. The invention also relates to a method of eliminating or reducing the amount of nitrogenous compounds, notably ammonia, in the intestine of a subject in need thereof, comprising administering to said patient a therapeutically effective amount of a formulation as described above.
[0164] When the individual to be treated is an animal, for example a pet or farm animal, the formulation according to the invention can be incorporated into the food. For example, the formulation according to the invention can be incorporated into a medical food (or drug food) without or with an antibiotic, if the food is intended to be used as a therapeutic formulation. Alternatively, the formulation according to the invention may be in the form of a premix food, which will serve as a food additive. VETERINARY APPLICATIONS:
[0165] The formulation according to the invention is capable of releasing an adsorbent in a specific part of the intestine of an individual. As mentioned above, the individual can be a pet or a farm animal. For example, the individual may be a pig, dog, cat, horse or poultry.
[0166] Adsorbents, in addition to being useful in a therapeutic context, are capable of eliminating a wide range of molecules. Consequently, the formulations according to the invention can be implemented in methods where the release of an adsorbent in the lower parts of the intestine would be advantageous.
[0167] For example, the formulation according to the invention can be used to reduce flatulence (for example through adsorption of H2S), fecal odor (for example through adsorption of ammonium), halitosis, food intolerance, etc. .
[0168] The present invention will be further understood with reference to the following non-limiting examples. EXAMPLES EXAMPLE 1: ADSORPTION KINETIC OF LEVOFLOXACIN BY CARBON ACTIVATED IN SIMULATED COLONIC FLUID
[0169] A solution of levofloxacin (50 μg/ml) was incubated without any formulated activated carbon (NFAC) in simulated colonic fluid (50 mM sodium phosphate buffer pH 6.0, 100 mM NaCl) with gentle mixing at 37°C. The ratio of NFAC to levofloxacin was 3:1 or 10:1.
[0170] Samples were taken after 0, 0.5, 1 and 2 h of incubation, centrifuged and filtered, and the amount of levofloxacin remaining in the supernatant was measured by its absorbance at 287 nm.
[0171] As shown in Figure 1, even with the lowest ratio of NFAC to levofloxacin, all antibiotics were adsorbed onto charcoal after 30 min of incubation. EXAMPLE 2: MICROBIOLOGICAL ASSAY OF CIPROFLOXACIN AND LEVOFLOXACIN
[0172] The microbiological test consists of measuring the biological activity of an antibiotic, that is, its ability to inhibit the growth of an indicator bacterial strain. For this purpose, agar plates were made with Difco 5 medium, containing the E. coli strain CIP 7624 as an indicator strain. 20 μl samples containing the antibiotic to be measured were stained on paper discs applied directly to the surface of the agar plates. After 18 h of incubation at 37°C, the diameters of the zones around the paper discs where bacterial growth was inhibited by the presence of the antibiotic were measured.
[0173] As shown in Figure 2, there is a linear relationship between the log of the concentration of the antibiotic solution (log10 μg/ml) and the diameter (mm) of growth inhibition. The assay was linear from 0.04 to 5 μg/ml of ciprofloxacin.
[0174] When 20 μl of an unformulated charcoal suspension was smeared on the discs, no growth inhibition was observed, showing that charcoal alone had no effect on bacterial growth in this assay.
[0175] A similar trial was fitted to levofloxacin using the same medium and indicator strain; this assay gave a linear response of 0.15 to 10 µg/ml of levofloxacin (not shown). EXAMPLE 3: CYPROFLOXACIN ABSORPTION KINETICS BY ACTIVATED CARBON MEASURED BY MICROBIOLOGICAL ASSAY
[0176] A ciprofloxacin solution (50 μg/ml) was incubated with 150 μg/ml of activated charcoal in simulated modified colonic fluid (18.7 mM maleic acid, 84 mM NaCl, pH 6.0). Samples were taken at various times, centrifuged, and the amount of ciprofloxacin remaining in the supernatant was measured by a microbiological assay as described in example 2. As shown in Figure 3, the result was essentially the same as in the experiment described in example 1 , where antibiotic concentrations were measured spectrophotometrically. Most of the antibiotic was absorbed onto charcoal within an hour. It is noteworthy that the sample marked as taken at time zero actually represented approximately one minute of contact between ciprofloxacin and charcoal; within this short period of time, charcoal has already absorbed close to 70% of the antibiotic. EXAMPLE 4: ABSORPTION KINETIC OF LEVOFLOXACIN BY ACTIVATED CARBON IN CECAL MEDIUM
[0177] In order to mimic the conditions under which activated charcoal would interact with antibiotics in vivo, we measured the absorption of levofloxacin onto activated charcoal in the presence of intestinal medium collected from the cecum of healthy piglets (ex vivo conditions).
[0178] Levofloxacin (800 μg/ml) was pre-incubated with an equal volume of piglet cecal medium for 2 h at 37°C with gentle agitation. Similarly, a suspension of unformulated activated charcoal, or deformulated product (unformulated coated pellets, or DCP) containing 80 mg/ml of equivalent activated charcoal were incubated under the same conditions as above with an equal volume of piglet cecal medium. Deformulation is carried out as provided in Example 6 below. Antibiotic and charcoal suspensions in cecal medium were then mixed in equal volumes, and incubated for up to 5 h at 37°C with gentle agitation; this represented a 100:1 ratio of charcoal to levofloxacin. At the indicated times, samples were removed, centrifuged, and the amount of free and active antibiotic remaining in the supernatant was measured by the microbiological assay described above. Figure 4 shows that approximately half of the antibiotic was absorbed into the cecal medium, reaching equilibrium for one hour. In the presence of activated charcoal, no free and active antibiotics remained in the supernatant after one hour, showing that even in the presence of high amounts of real intestinal medium, activated charcoal was able to efficiently absorb levofloxacin. The experiment further shows that the activated charcoal formulation did not affect its ability to absorb levofloxacin under such ex vivo conditions.
[0179] The experiment was carried out with cecal medium extracted from two different piglets; the mean ± SD for triplicate determinations is shown. EXAMPLE 5: DESORPTION OF LEVOFLOXACIN UNDER DIFFERENT CONDITIONS
[0180] Levofloxacin (final concentration 200 μg/ml) was adsorbed onto unformulated activated charcoal (NFAC) or unformulated coated pellets (DCP) in the presence of piglet cecal medium as described in example 4, except that the charcoal ratio activated to levofloxacin was 50:1 in these experiments. After a 2 h incubation of Levofloxacin with cecal medium and charcoal, the medium was centrifuged, the pellet containing charcoal particles and cecal medium was washed 3 times, and finally incubated for up to 30 days in 50 mM phosphate buffer sodium, containing 100 mM NaCl, at pH 4.0, 7.0 or 10.0 with gentle agitation at 22°C. A control was carried out with cecal medium, but in the absence of charcoal; dissociation experiments were performed in the same volume as the original incubation. At the indicated times, a sample was removed, centrifuged, and the amount of free and active antibiotic released into the medium was measured from the supernatant by a microbiological assay.
[0181] Figure 5 shows that some of the antibiotic was released from the material into the cecal medium over time, and that this amount was much more important at pH 10.0 than at pH 4.0 and 7.0. A lower amount of levofloxacin was released in the presence of NFAC. Very markedly, at pH 4.0 and 7.0, the amount of charcoal released in the presence of DCP was below the detection limit (0.15 μg/ml of levofloxacin). At pH 10.0, the release of levofloxacin was measurable, but did not exceed 2 μg/ml, representing 1% of the original amount of antibiotic in the experiment. Consequently, at pH values likely to be found in the natural environment, dissociation of levofloxacin from activated charcoal contained in DCP may not be measured. EXAMPLE 1: EFFECTIVENESS OF ABSORPTION OF OTHER ANTIBIOTICS ON ACTIVATED CARBON
[0182] The assay conditions were as follows: experiments were performed in phosphate buffer saline (PBS) at pH 6 adjusted for colonic osmolarity, an initial amount of antibiotic of 200 μg/ml was tested (or less accordingly with maximum drug solubility), activated charcoal/antibiotic ratios of 3/1 and 10/1 were tested, incubation for 2 h at 37° C (15 ml polypropylene tube, slow rotation 20 rpm), sampling at 0.5 h, 1 h and 2 h, Residual antibiotic dosage (ie, unabsorbed) was determined by UV/visible spectrometric analysis.
[0183] The results are shown in Tables 1 and 2. Table 1: In vitro absorption of various antibiotics commonly administered to humans

(*) If the antibiotic is not completely absorbed after 30 min at 3/1 or 10/1 ratio, then extra charcoal is added after 1 and 2 hours ATB is an abbreviation for antibiotic Table 2: Absorption ex of various antibiotics commonly administered to humans.



[0184] Nord, C.E., et al. "Effect of piperacillin/tazobactam treatment on human bowel microflora." J.Antimicrob.Chemother. 31 Suppl A (1993): 61-65.
[0185] Pletz, M.W., et al. "Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers." Antimicrob.AgentsChemother. 48.10 (2004): 3765-72. (Pletz et al. 3765-72)
[0186] Kager, L., et al. "Effect of imipenem treatment versus imipenem surgical prophylaxis on the intestinal microflora." Int.J.Clin.Pharmacol.Res. 8.6 (1988): 441-47.
[0187] Brismar, B., C. Edlund, and C.E. Nord. "Comparative effects of clarithromycin and erythromycin on the normal intestinal microflora." Scand.J.Infect.Dis. 23.5 (1991): 635-42. (Brismar, Edlund, and Nord 635-42)
[0188] Edlund, C., et al. "Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora." Scand.J.Infect.Dis. 32.1 (2000): 81-85. (Edlund et al. 81-85)
[0189] Edlund, C., S. Sjostedt, and C.E. Nord. "Comparative effects of levofloxacin and ofloxacin on the normal oral and intestinal microflora." Scand.J.Infect.Dis. 29.4 (1997): 383-86. (Edlund, Sjostedt, and Nord 383-86)
[0190] As shown in the tables above, most antibiotics tested can be significantly absorbed onto activated charcoal, in a ratio that can be extrapolated in humans as clinically relevant. In vivo data correlate well with ex vivo data and where data are available from the literature, it can be seen that the amount of residual antibiotic found in faeces can be easily removed with activated charcoal formulation. EXAMPLE 7: PHARMACEUTICAL FORMULATION
[0191] The feasibility of an oral dosage form for site-specific delivery of activated charcoal has been investigated by testing different pharmaceutical formulation processes. The objective was to develop a dosage form suitable for the delayed release of activated charcoal in the last part of the gastrointestinal tract while still preserving as much as possible the absorption characteristics of charcoal.
[0192] Activated carbon is a very challenging product to formulate because of its physicochemical properties such as low density, hydrophobicity, wetting properties, etc. Attempts to formulate charcoal for the intended use described in this invention at a therapeutic dose for human administration have not been possible using conventional direct compression because of the very low cohesive properties of activated charcoal. Even simple wet granulation and compression lead to tablets that exhibit poor absorption properties. The inventors, however, have trained to formulate activated carbon in large quantities in delivery systems that evoke very good stability and disintegration properties: a fast and efficient dispersion of activated carbon in solution is obtained. Furthermore, the absorption properties of activated carbon are preserved in the described formulation.
[0193] The Table below shows an example of pellets obtained by wet granulation followed by extrusion spheronization. Table 3: Example of a charcoal pellet formulation obtained by wet granulation with carrageenan.

[0194] These pellets form the core of the formulations used throughout the present examples.
[0195] These pellets are then further coated with a specific pH-dependent polymeric coating, such as Eudragit® FS30D or Eudragit® L30D55 (Evonik, Darmstadt, Germany) for example.
[0196] The ability of formulated and unformulated activated charcoal to absorb various antibiotics under simulated colonic conditions has been studied in absorption kinetic studies.
[0197] For this purpose, activated charcoal coated pellets were first deformulated in a buffer (50 mM sodium phosphate buffer, 80 mM NaCl, pH 7.5) for at least 30 minutes at 37°C. Unformulated activated charcoal (NFAC) suspensions were also prepared in this buffer. Then, the absorption capacity of a suspension of deformulated pellets (formulation) and an NFAC suspension was tested with a levofloxacin solution (levo).
[0198] Figure 6 presents, as an example, a comparison of various levofloxacin absorption kinetics in NFAC and deformulated pellets. The experiments were carried out as in the previous example, with pellets coated with 20% Eudragit FS30D.
[0199] Two studied ratios of NFAC to levofloxacin and deformulated pellets to levofloxacin are presented, 3:1 and 10:1. A control sample, made from the levofloxacin solution, was also analyzed during absorption kinetics.
[0200] Complete absorption of levofloxacin in the deformulated pellets and NFAC is observed after 60 minutes for the ratio of 10:1. Absorption is nearly complete at the ratio of 3:1 in the formulation and complete in NFAC. Consequently, the absorption properties of activated carbon are essentially maintained through the formulation processes.
[0201] The limited influence of time, temperature and humidity can be observed under bulk storage conditions of the formulation. Excellent stability was obtained at room temperature after 9 months under bulk storage conditions as determined by measuring the disintegration and absorption time of ciprofloxacin after one hour.
[0202] More precisely, the stored pellets were disintegrated in simulated colonic medium (50 mM sodium phosphate buffer, 80 mM NaCl, pH 7.5) and reinforced with a known amount of ciprofloxacin. The disintegration kinetics of the pellets were monitored. As the pellets disintegrate and release activated charcoal, the ciprofloxacin concentration in the solution decreases. The results presented in Table 4 below represent the percentage of ciprofloxacin remaining in the medium at different sampling times. These results prove that the disintegration properties of the pellets are maintained for 9 months under bulk storage conditions. Table 4: Bulk stability of FS30D coated charcoal formulation stored at room temperature in glass vials. The charcoal/ciprofloxacin formulation ratio was 9:1. Results are expressed as the percentage of free ciprofloxacin remaining in solution.
EXAMPLE 8: IN VITRO RELEASE PROFILE OF ACTIVATED CARBON AND CIPROFLOXACIN ABSORPTION KINETIC
[0203] One of the main problems with the charcoal formulation is the disintegration profile of the charcoal pellet in the medium to allow maximum efficiency of absorption. The formulation described earlier was tested in a BioDis dissolution tester (USP III release apparatus) using various simulated intestinal media reinforced with ciprofloxacin at a concentration of 50 μg/mL. In this experiment, approx. 73 mg of coated pellets were submitted to dissolution in the BioDis system, by successive incubation for the times indicated in media whose composition reflects the pH, buffer capacity and osmolarity of the various gastrointestinal compartments. Samples from each medium were taken and analyzed to determine the concentration of ciprofloxacin remaining. Ciprofloxacin was only absorbed by active charcoal released from the formulation, hence ciprofloxacin absorption was considered as a release from the representative or active charcoal formulation.
[0204] The simulated gastro-intestinal media are described below: Simulated gastric media: 34.2 mM NaCl, pH adjusted to 1.6 with HCl. Medium from simulated duodenum and proximal jejunum: 19.1 mM maleic acid, 70 mM NaCl, 31.6 mM NaOH, pH = 6.5 Medium from simulated intermediate and posterior jejunum: 25 mM HEPES, 121.6 mM of NaCl, pH adjusted to 7.0 Simulated ileal medium: 18 mM HEPES, 132.1 mM NaCl, pH adjusted to 7.5 Simulated colonic medium: 18.7 mM maleic acid, 83.7 mM NaCl, 25.6 mM NaOH, pH adjusted to 6.0
[0205] As shown in Figure 7, the carrageenan-based carrageenan formulation coated with FS30D, as a coating example, did not demonstrate any release of charcoal until reaching pH 7.5. Thereafter, absorption of ciprofloxacin was very rapid and complete within half an hour after charcoal dispersion. EXAMPLE 9: OTHER POSSIBLE FORMULATIONS
[0206] Antibiotics have different absorption profiles in mammals, some being absorbed early and some being absorbed later. The late one will reach its maximum plasma concentration after 2 to 4 hours. The formulations can be developed to allow longer absorbent delivery to avoid any impact on the normal antibiotic absorption process.
[0207] To obtain such a delayed release, pellet formulations were first coated with a subcoat that prevents them from disintegrating too fast and delayed disintegration by 30 minutes to 2 hours, depending on the type of polymer used for the sub- coating.
[0208] Several formulations have been obtained using multiple coating techniques. Table 5 below presents some examples of coating combinations. Table 5: Formulations with multiple subcoats and final coating with FS30D

*: the numbers in parentheses represent the respective proportions of the Eudragit polymers indicated in the mixture used to prepare the pellet subcoat or other coating.
[0209] Dissolution tests were performed on these pellets in simulated ileal medium, pH 7.5 to assess the dispersion kinetics of the pellet in such a medium and compare the delays obtained. The ileum medium was reinforced with 50 μg/mL of ciprofloxacin, and at each sampling time, the amount of residual ciprofloxacin remaining in the solution was quantified; ciprofloxacin absorption was considered as a proxy for charcoal release.
[0210] BioDis tests were also performed on these pellets, as described above, in order to mimic their progression through the gastrointestinal tract. This allowed for a more detailed characterization of the delayed release of charcoal from the pellets.
[0211] Figures 8 to 10 describe the release of charcoal, measured as ciprofloxacin absorption, from some of the formulations described in Table 5.
[0212] As can be seen in Figure 8, a first coating (subcoating) made of a blend of L30D55/NE30D polymers representing 35% w/w of the final weight of the pellets evoked a delayed absorption of ciprofloxacin, meaning that charcoal The vegetable exhibited a delayed release of charcoal when compared to the formulation made with an external FS30D coating at approx. 30 minutes.
[0213] As can be seen in Figure 9, the coated Aqoat pellets exhibited a dissolution that was approx 30 min faster than those coated with an equivalent amount of FS30D. Absorption of ciprofloxacin was complete within one hour. For the shellac coated pellets, delayed dissolution was observed for the film and disintegration of the charcoal pellets was prolonged for at least two hours
[0214] As can be seen in Figure 10, the effect of various thicknesses of ethylcellulose coatings was evaluated on pellet dissolution. An intermediate coating consisting of 2% ethylcellulose induced a significant delayed release of activated carbon, in approximately 40 minutes to an hour, compared to 20% FS30D coating.
[0215] Such formulations would be of interest in providing delayed and prolonged release of the absorbent. EXAMPLE 10: IN VITRO ABSORPTION KINETIC OF IRINOTECAN AND SN-38 ON ACTIVATED CARBON
[0216] The absorption kinetics of irinotecan and its active metabolite SN-38 on active charcoal was determined in vitro (Figures 11A and 11B respectively).
[0217] The capacity of activated charcoal to absorb irinotecan (200 μg/mL of initial concentration) was evaluated in simulated ileal medium (18 mM HEPES, 132.1 mM NaCl, adjusted to pH 7.5 with NaOH). The respective proportions of activated carbon and irinotecan were 3:1 and 10:1 in relation to irinotecan. The samples were centrifuged, filtered, and diluted ten-fold, before determining the unabsorbed concentration of irinotecan by measuring its absorbance at 368 nm using a spectrophotometer. As can be seen in Figure 11A, half the amount of irinotecan was absorbed in about 12 minutes with a 3:1 activated charcoal/irinotecan ratio. Complete absorption was achieved in about 15 minutes with a 10:1 activated charcoal/irinotecan ratio.
[0218] Figure 11B shows the ability of activated charcoal to absorb SN-38. SN-38 was dissolved at a concentration of 50 μg/mL in 0.01 M NaOH pH 12. Unabsorbed SN-38 was detected after centrifugation and filtration by its absorbance at 411 nm using a spectrophotometer. As can be seen in Figure 11B, SN38 absorption was complete in about 30 minutes with an activated charcoal/SN-38 ratio of 10:1.
[0219] The absorption kinetics of irinotecan and its metabolite SN-38 on activated charcoal (NFAC) (Figure 11C) and the charcoal released from the unformulated coated pellets (DCP) (20% FS30D coating) (Figure 11D) were determined ex vivo, in piglet cecal medium.
[0220] Piglet cecal medium was reinforced with 250 µg/ml irinotecan and 50 µg/ml SN-38, and pre-incubated for 2 h at 37°C. NFAC or DCP were pre-incubated with diluted piglet cecal medium 1:1 for 2 hours at 37°C. The ratios for NFAC/irinotecan were 10:1, 50:1, and those for NFAC/SN38 were 10:1, 50:1, 100:1 and 250:1; the ratios of active charcoal from DCP to irinotecan and SN38 were 10:1 and 50:1.
[0221] After combining these two mixed pre-incubation mixes, the incubation was carried out at 37°C with gentle agitation for the indicated periods of time. Samples were removed, centrifuged, the supernatant was filtered and analyzed for the presence of irinotecan and SN38 by HPLC. EXAMPLE 11: IN VIVO PERFORMANCE OF TARGETED RELEASE ACTIVATED CARBON IN REDUCING THE EMERGENCY OF BACTERIAL RESISTANCE TO ANTIBIOTIC
[0222] A proof-of-concept (POC) study of the ability of targeted-release activated carbon (activated carbon coated pellets) to reduce the emergence of bacterial resistance during antibiotic treatments was carried out in piglets, which were weaned 4 weeks later. birth, and included in the study two weeks after that.
[0223] The study was randomized, comparative, open to life stage but blinded to treatment for the evaluation of microbiological and PK/PD data to demonstrate the effectiveness of the charcoal delayed-release formulation to: Decrease faecal antibiotic concentrations Prevent the emergence of bacterial resistance in the intestinal flora. Keep the antibiotic absorption process normal.
[0224] To perform this POC in vivo, the antibiotic to be tested was ciprofloxacin, a fluoroquinolone, administered orally at a dose of 1.5 mg/kg/day. This type of study will apply to any antibiotic considered by Da Volterra. The methods used to assess the decrease in faecal antibiotic concentrations and the emergence of bacterial resistance were developed by Da Volterra. The experiments were carried out under GLP conditions. Piglets from the same batch were not treated with antibiotics since birth.
[0225] The study design is represented in Figure 12.
[0226] The primary endpoints of this study were: Pharmacokinetic Criteria: - To compare the concentration of ciprofloxacin with or without coated pellets in stool by comparing the neperian logarithm of Area Under the Curve (AUC) of fecal ciprofloxacin concentrations between Day 1 and Day 9 (logAUCD1-D9).
[0227] AUC between Day 1 and Day 9 was computed by the trapezoidal method using SAS software and is analyzed with descriptive statistics and compared across groups by t tests (in logAUCD1-D9). - To compare plasma ciprofloxacin concentrations with or without coated pellets by comparing the Neperian Area Under the Curve (AUC) logarithm of plasma ciprofloxacin concentrations between 0 h and the Last time corresponding to the last observed value (logAUC) (this choice of AUC0 -last can be explained by the very high extrapolation percentages for AUCo-~)
[0228] The neperian log of maximum plasma ciprofloxacin concentration (Cmax) (logCmax).
[0229] This was performed by a Non-Compartmental Method (NCA), linear/log trapezoidal method, through the WinNonLin software (version 5.2) to compute Cmax and AUC. Plasma concentrations of ciprofloxacin at 0 h were considered to be 0 ng/ml. Log AUC and logCmax were then calculated and analyzed with descriptive statistics.
[0230] Pharmacodynamic criteria:
[0231] To compare the number of resistant bacteria after ciprofloxacin treatment with or without coated pellets by comparing the AUC of ciprofloxacin and nalidixic acid resistant Enterobacteriaceae counts from Day 1 to Day 6 (treatment) normalized for Days -1/1. Bacterial counts were obtained by performing a 100 μl dilution at 1/10 of feces plated on Drigaski agar. Counts of ciprofloxacin and nalidixic acid resistant Enterobacteriaceae were obtained by plating diluted stools on Drigaski agar with 2 ml/l ciprofloxacin and 20 ml/l nalidixic acid. The detectable limit of resistant Enterobacteriaceae counts was 1.00 x 102 CFU/g. The reference value was calculated from the mean resistant bacteria content before treatment and the area under the curve is the area between the reference value and the log10 curve of ciprofloxacin resistant Enterobacteriaceae counts. RESULTS
[0232] Coated pellets associated with ciprofloxacin were able to decrease residual fecal concentrations of ciprofloxacin in piglets. The decrease was statistically significant. Comparative results of ciprofloxacin concentration in faeces are shown in Figure 13 and are summarized in Table 6. Table 6: Faecal ciprofloxacin concentrations: descriptive statistics on individual D1-D9 log AUC by group (n1 = 6, n2 = 11, n3 = 12)

[0233] The log AUC D1-D9 difference between Group 2 (ciprofloxacin/placebo) vs. Group 3 (ciprofloxacin/coated pellets) was statistically significant by t-test comparison (p value < 0.0001).
[0234] There were also significant differences between Group 1 (placebo/placebo) vs. Group 2 (ciprofloxacin/placebo) (p value < 0.0001) and between Group 1 (placebo/placebo) vs. Group 3 (ciprofloxacin/Dav-132) (p value < 0.0001).
[0235] The administration of the coated pellets associated with the administration of ciprofloxacin does not result in a significant change in the plasma concentration of ciprofloxacin. The results on plasma ciprofloxacin concentration are shown in Figure 14 and are summarized in Table 7. Table 7: Plasma ciprofloxacin concentrations: descriptive statistics on individual log AUC and log Cmax per group (n2 = n3 = 12)

[0236] The results show that there is no significant difference between these 2 groups in logAUC (t-test p-value = 0.28) and logCmax (t-test p-value = 0.51). Administration of coated pellets together with ciprofloxacin resulted in a decrease in bacterial resistance due to the residual concentration of ciprofloxacin in faeces (see Figure 15).
[0237] Ciprofloxacin-resistant Enterobacteriaceae counts in faeces significantly increase with ciprofloxacin treatment of piglets. The charcoal formulations according to the invention administered with ciprofloxacin significantly reduced the emergence of bacterial resistance as shown in Table 8. The control group (placebo/placebo) showed no emergence of resistance. Table 8: Resistant bacterial counts: descriptive statistics of individual AUC between Day 1 and Day 6 for ciprofloxacin and nalidixic acid
CONCLUSIONS
[0238] The results showed that the formulations according to the invention were: - Well tolerated by the piglets - Able to significantly reduce the concentration of ciprofloxacin in faeces after administration for a period of five days together with oral ciprofloxacin - Able to significantly reduce the emergence of bacterial resistance to antibiotic treatment - Able to have no interference with the normal process of absorption of ciprofloxacin EXAMPLE 12: IN VITRO KINETICS OF PANCREATIC ENZYME ABSORPTION ON ACTIVATED CARBON
[0239] The absorption kinetics of Creon, a drug containing pancreatic enzymes, on active charcoal was determined in vitro (Figure 16). The degree of enzyme uptake on activated charcoal was assessed using a protein quantitation assay (Bradford method). The ability of activated charcoal to absorb pancreatic enzymes (1 mg/ml Creon) was assessed in buffer (50 mM sodium phosphate buffer, 80 mM NaCl, adjusted to pH 7.5). The respective proportions of activated carbon and Creon were 9:1, 15:1 and 25:1. Samples were centrifuged, the supernatant was filtered, and the amount of residual protein was quantified using a Bradford protein assay. A 1 mg/ml Creon solution, and a 3 mg/ml activated charcoal suspension were respectively used as positive and negative controls. As can be seen in Figure 16, complete absorption of the enzymes was achieved in 2 hours with a 15:1 ratio and in 1 hour with a 25:1 ratio.

权利要求:
Claims (19)
[0001]
1. Formulation, characterized in that it comprises - a core containing active carbon mixed with carrageenan, in the form of a pellet, in which the amount of carrageenan is comprised between 5% and 25% by weight of the core, and - a layer of a outer coating formed around the core such that active carbon is released from the formulation in the lower intestine, where the outer coating is a pH-dependent enter-soluble polymer that dissolves at a pH of 6.0 and above.
[0002]
2. Formulation according to claim 1, characterized by the fact that carrageenan is a cap-carrageenan.
[0003]
3. Formulation according to claim 1, characterized in that the amount of carrageenan is comprised between 10% and 20% by weight of the core.
[0004]
4. Formulation according to claim 1, characterized by the fact that the pH-dependent enter-soluble polymer is selected from the group consisting of cellulose acetate trimellitate (CAT), cellulose acetate phthalate (CAP), anionic acrylate-based copolymers of methyl, methyl methacrylate and methacrylic acid, hydroxypropyl methylcellulose phthalate (HPMCP), hydroxypropylmethylcellulose acetate succinate (HPMCAS), copolymers of methacrylic acid and ethyl acrylate, copolymer of methacrylic acid and ethyl acrylate, copolymers of methacrylic acid and methyl methacrylate (1:1 ratio), methacrylic acid copolymers and methyl methacrylate (1:2 ratio), Polyvinyl acetate phthalate (PVAP) and Shellac resins.
[0005]
5. Formulation according to claim 1, characterized in that the pH-dependent polymer is selected from the group consisting of - shellac, - hydroxypropylmethylcellulose acetate succinate - hydroxypropylmethylcellulose phthalate - anionic copolymers based on methyl acrylate, methyl methacrylate and methacrylic acid, and - copolymers of methacrylic acid and methyl methacrylate (1:2 ratio).
[0006]
6. Formulation according to claim 1, characterized in that the outer coating is a mixture of methyl methacrylate and methacrylic acid, and copolymer of methacrylic acid and ethyl acrylate, in a ratio between 99:1 and 80: 20.
[0007]
7. Formulation according to claim 1, characterized in that another coating is provided between the core and the outer pH-dependent layer.
[0008]
8. Formulation according to claim 7, characterized in that said other coating being selected from the group consisting of - pH dependent polymers, - pH independent water soluble polymers - pH independent insoluble polymers and - dependent polymer mixtures of pH and a water-insoluble, pH-independent polymer.
[0009]
9. Formulation according to claim 8, characterized in that said pH-dependent polymers are selected from the group consisting of shellac polymers, anionic copolymers based on methyl acrylate, methyl methacrylate and methacrylic acid, copolymer of methacrylic acid and ethyl acrylate, hydroxypropyl methylcellulose phthalate (HPMCP), hydroxypropyl methylcellulose acetate succinate (HPMCAS).
[0010]
10. A formulation according to claim 8, characterized in that said pH-independent water-soluble polymers are selected from the group consisting of PVP or high molecular weight cellulose polymers.
[0011]
11. Formulation according to claim 8, characterized in that said insoluble pH-independent polymers are selected from the group consisting of ethylcellulose polymers and copolymer of methyl methacrylate and ethyl acrylate.
[0012]
12. Formulation according to claim 8, characterized in that said mixtures of pH-dependent and water-insoluble polymer, pH-independent polymer are selected from the group consisting of ethylcellulose or ethyl acrylate methyl methacrylate copolymer (NE30D) .
[0013]
13. Formulation according to claim 8, characterized in that the pH-independent dissolving polymer layer comprises at least one cellulose derivative selected from the group consisting of hydroxypropylcellulose and ethylcellulose.
[0014]
14. Formulation according to claim 8, characterized in that the pH-independent dissolving polymer layer is made of a 1:9 to 9:1 mixture of methacrylic acid and ethyl acrylate copolymer and ethyl methacrylate copolymer. methyl ethyl acrylate.
[0015]
15. Formulation according to claim 14, characterized in that the pH-independent dissolving polymer layer is made of a 2:8 to 3:7 mixture of methacrylic acid and ethyl acrylate copolymer and methacrylate copolymer of methyl ethyl acrylate.
[0016]
16. Use of a formulation as defined in claim 1, characterized by the fact that it is used in the manufacture of a medicine to eliminate or reduce the side effects in the intestine of pharmaceutical agents that are administered as a treatment for a disorder, but which have effects collaterals when they, or a metabolite or derivative thereof, reach the ileum, cecum or colon, wherein the pharmaceutical agent is selected from the group consisting of an antibiotic agent and irinotecan.
[0017]
17. Use of a formulation according to claim 16 for use in a method to eliminate or reduce the emergence of bacterial antibiotic resistance or to eliminate or reduce diarrhea.
[0018]
18. Use of a formulation, according to claim 16, characterized by the fact that said antibiotic and said formulation are administered simultaneously orally.
[0019]
19. Use of a formulation according to claim 16, characterized by the fact that said metabolite of Irinotecan is SN-38.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US11202761B2|2021-12-21|Formulations for oral delivery of adsorbents in the gut

---

AU2007251565B2|2012-06-28|Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules

---

JP5845173B2|2016-01-20|Orally disintegrating tablet composition comprising a combination of a non-opioid and an opioid analgesic

---

BRPI0608853B1|2020-05-19|pharmaceutical compositions and process for the manufacture of gastro-resistant rifaximin microgranules

---

JP2012520268A|2012-09-06|Compositions and methods for removal of gram-negative bacteria

---

BRPI0615014A2|2011-05-03|solid pharmaceutical composition comprising 1- | -4- | phthalazine and a ph modifier and use thereof

同族专利:

---

公开号 | 公开日

---

CY1117869T1|2017-05-17|

---

RU2016147198A|2018-06-01|

---

HK1180233A1|2013-10-18|

---

CN102869351A|2013-01-09|

---

US20130052269A1|2013-02-28|

---

CA2790811C|2017-12-05|

---

KR101820374B1|2018-01-19|

---

CN102869351B|2015-07-01|

---

LT2538930T|2016-09-26|

---

HRP20160834T1|2016-09-23|

---

US20180369156A1|2018-12-27|

---

JP2013520467A|2013-06-06|

---

AU2011219788B2|2015-05-14|

---

US20170296478A1|2017-10-19|

---

RS54991B1|2016-11-30|

---

US9968562B2|2018-05-15|

---

CA2790811A1|2011-09-01|

---

ES2586135T3|2016-10-11|

---

US11202761B2|2021-12-21|

---

PT2538930T|2016-08-05|

---

AU2011219788A1|2012-09-06|

---

MX340822B|2016-07-26|

---

KR20130044214A|2013-05-02|

---

WO2011104275A1|2011-09-01|

---

MX2012009728A|2012-11-29|

---

RU2681315C2|2019-03-06|

---

HUE029299T2|2017-02-28|

---

JP5645975B2|2014-12-24|

---

SI2538930T1|2016-10-28|

---

PL2538930T3|2016-11-30|

---

US10052288B2|2018-08-21|

---

IL221542A|2017-06-29|

---

BR112012021275A2|2016-10-25|

---

EP2538930A1|2013-01-02|

---

RU2016147198A3|2018-06-01|

---

ZA201207068B|2013-05-29|

---

EP2538930B1|2016-06-15|

---

RU2012140421A|2014-03-27|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US3917821A|1973-10-23|1975-11-04|Milton Manes|Palatable activated carbon|

---

US4761284A|1977-12-27|1988-08-02|Kureha Kagaku Kogy Kabushiki Kaisha|Antidote including activated carbon particles|

---

JPS5542210A|1978-09-12|1980-03-25|Koichi Ogawa|Special activated carbon|

---

JPS62168540A|1986-01-21|1987-07-24|Freunt Ind Co Ltd|Coating method|

---

KR950014441B1|1986-08-28|1995-11-28|코르텍스 리미티드|Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals|

---

US5597564A|1986-08-28|1997-01-28|Enzacor Properties Limited|Method of administering a microgranular preparation to the intestinal region of animals|

---

US5356625A|1986-08-28|1994-10-18|Enzacor Properties Limited|Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals|

---

GB8812490D0|1988-05-26|1988-06-29|Agricultural & Food Res|Delayed release formulations|

---

JPH03120227A|1989-10-02|1991-05-22|Shigeo Ochi|Agent for absorbing and suppressing digested and degraded product of food and drink|

---

IT1246382B|1990-04-17|1994-11-18|Eurand Int|METHOD FOR THE TARGETED AND CONTROLLED DELIVERY OF DRUGS IN THE INTESTINE AND PARTICULARLY IN THE COLON|

---

JP3338119B2|1993-04-14|2002-10-28|呉羽化学工業株式会社|Antidiabetic agent|

---

US5827497A|1996-08-14|1998-10-27|Mayo Foundation For Medical Education And Research|Charcoal-radionuclide agents for measurement of gastrointestinal transit|

---

FR2780052B1|1998-06-23|2000-07-21|Ceca Sa|ACTIVATED CARBON AGGLOMERATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ADSORPTION AGENTS|

---

CA2406208A1|2000-04-21|2001-11-01|Watervisions International, Inc.|Formation of composite materials with expandable matter|

---

WO2002057477A1|2001-01-19|2002-07-25|Rhodia Chimie|Process for producing carrageenan with reduced amount of insoluble material|

---

CA2344910C|2001-04-23|2009-07-07|Kureha Chemical Industry Co., Ltd.|Method for treating renal disease, and pharmaceutical composition for treating renal disease|

---

EP1306128A1|2001-10-29|2003-05-02|Tenaxis Gmbh|Sorptive composite materials|

---

JP4486300B2|2002-07-25|2010-06-23|ユニ・チャーム株式会社|Absorbent article top sheet|

---

FR2843302B1|2002-08-09|2004-10-22|Centre Nat Rech Scient|GALENIC FORM FOR COLLECTIVE DELIVERY OF ACTIVE PRINCIPLES|

---

JP3585043B2|2003-01-22|2004-11-04|メルク・ホエイ株式会社|Pharmaceutical adsorbent and its production method|

---

KR20060011960A|2003-04-25|2006-02-06|고키붓산 유겐가이샤|Agent for preventing and ameliorating constipation|

---

GB2405343A|2003-08-29|2005-03-02|Johnson & Johnson Medical Ltd|Charcoal Wound Dressings|

---

JP4409245B2|2003-10-20|2010-02-03|株式会社荏原製作所|Apparatus using coating alloy having corrosion resistance and wear resistance|

---

KR101135260B1|2003-10-22|2012-04-12|가부시키가이샤 쿠레하|Adsorbent for oral administration, and agent for treating or preventing renal or liver disease|

---

TWI370012B|2004-04-02|2012-08-11|Kureha Corp|Adsorbent for oral administration, and agent for treating or preventing renal or liver disease|

---

CN1964699B|2004-06-07|2010-12-08|株式会社吴羽|Dry-form composition for oral ingestion and gel-form composition for oral ingestion of type prepared at time of use|

---

CA2581002C|2004-10-15|2012-01-10|Supernus Pharmaceuticals, Inc.|Less abusable pharmaceutical preparations|

---

US9149439B2|2005-03-21|2015-10-06|Sandoz Ag|Multi-particulate, modified-release composition|

---

PT1883396E|2005-05-18|2013-10-08|Centre Nat Rech Scient|Colonic delivery of adsorbents|

---

NZ568023A|2005-11-07|2012-01-12|Russell M Jaffe|Compositions for regulating intestinal disorders and methods of use thereof|

---

US8557274B2|2005-12-06|2013-10-15|Purdue Research Foundation|Slowly digesting starch and fermentable fiber|

---

MX2008007418A|2005-12-06|2008-10-20|Ocera Therapeutics Inc|Use of adsorbent carbon microspheres for the treatment of irritable bowel syndrome.|

---

DE102005062160A1|2005-12-19|2007-06-21|BLüCHER GMBH|Activated charcoal for medical use|

---

US8048413B2|2006-05-17|2011-11-01|Helene Huguet|Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules|

---

US20080089943A1|2006-08-17|2008-04-17|Xavier Frapaise|Use of adsorbent carbon microspheres to treat gastroesophogeal reflux disease|

---

DE202006016898U1|2006-10-12|2007-11-22|BLüCHER GMBH|High performance adsorbents based on activated carbon with high microporosity|

---

JP2010510196A|2006-11-17|2010-04-02|ダ・ボルテラ|Colonic delivery using Eudragit-coated zinc / pectin beads|

---

WO2008073517A1|2006-12-07|2008-06-19|Ehrenpreis Eli D|Treatment for intestinal gas, bloating, microscopic colitis and traveler's diarrhea using colloidal bismuth subcitrate|

---

US20100036002A1|2006-12-26|2010-02-11|Medrx Co., Ltd.|Pharmaceutical composition comprising porous dry matrix|

---

DE102007009242A1|2007-02-22|2008-09-18|Evonik Röhm Gmbh|Pellets with enteric-coated matix|

---

WO2009049239A1|2007-10-12|2009-04-16|Ocera Therapeutics, Inc.|Use of adsorbent carbon microspheres to treat pouchitis|

---

DE102008014109A1|2008-03-13|2009-09-17|Bayer Animal Health Gmbh|Suspension formulation for carbon adsorbents|

---

KR20100001892A|2008-06-27|2010-01-06|주식회사 에코비젼|A granule of nitrifying microorganisms containing core particles and promoting method for forming a granule of nitrifying microorganisms|

---

FR2950252B1|2009-09-23|2012-01-20|Centre Nat Rech Scient|GALENIC FORM CAPABLE OF ADSORBER IN A SPECIFIC MANNER THE UNDESIRABLE MOLECULES|

---

JP5645975B2|2010-02-23|2014-12-24|ダ・ボルテラ|Formulation for oral delivery of adsorbents in the digestive tract|TWI281493B|2000-10-06|2007-05-21|Mitsui Mining & Smelting Co|Polishing material|

---

JP5645975B2|2010-02-23|2014-12-24|ダ・ボルテラ|Formulation for oral delivery of adsorbents in the digestive tract|

---

RS60901B1|2010-11-08|2020-11-30|Albireo Ab|Ibat inhibitors for the treatment of liver diseases|

---

CN102432737B|2011-09-07|2015-02-25|张绍国|Controlled-release enteric acrylic resin latex and preparation method thereof|

---

GB201204696D0|2012-03-16|2012-05-02|Ucl Business Plc|Therapy|

---

EP2897594B1|2012-09-21|2020-04-08|Ferring B.V.|Pharmaceutical composition|

---

EP2978413A1|2013-03-25|2016-02-03|Ferring BV|Composition for the treatment of disease|

---

CA2952406A1|2014-06-25|2015-12-30|Ea Pharma Co., Ltd.|Solid formulation and method for preventing or reducing coloration thereof|

---

CN108135927A|2015-10-06|2018-06-08|达·沃尔泰拉公司|Pathogenic or virulence the inhibition or reduction of Clostridia bacteria|

---

JPWO2017073531A1|2015-10-26|2018-08-09|第一三共株式会社|Delivery preparation of porous material to large intestine or lower intestine|

---

US10441604B2|2016-02-09|2019-10-15|Albireo Ab|Cholestyramine pellets and methods for preparation thereof|

---

JP6954927B2|2016-02-09|2021-10-27|アルビレオ・アクチボラグ|Oral cholestyramine preparation and its use|

---

US10441605B2|2016-02-09|2019-10-15|Albireo Ab|Oral cholestyramine formulation and use thereof|

---

US10786529B2|2016-02-09|2020-09-29|Albireo Ab|Oral cholestyramine formulation and use thereof|

---

KR101884520B1|2016-07-29|2018-08-02|한국식품연구원|Pharmaceutical compositions comprising bentonite for preventing or treating inflammatory bowel disease|

---

KR102106477B1|2017-01-12|2020-05-06|차장옥|Composition for preventing or treating Coccidiosis, preparation method of the same, and application of the same|

---

RU2020109469A3|2017-08-09|2022-01-14|

---

US10793534B2|2018-06-05|2020-10-06|Albireo Ab|Benzothiaazepine compounds and their use as bile acid modulators|

---

KR20210024032A|2018-06-20|2021-03-04|알비레오 에이비|Crystalline variant of odebiccibat|

---

JP2021534091A|2018-08-05|2021-12-09|ダ・ヴォルテッラ|How to improve the effectiveness of anticancer drugs|

---

KR20210040395A|2018-08-05|2021-04-13|다 볼떼라|Composition for the treatment of graft versus host disease|

---

US11007142B2|2018-08-09|2021-05-18|Albireo Ab|Oral cholestyramine formulation and use thereof|

---

US10722457B2|2018-08-09|2020-07-28|Albireo Ab|Oral cholestyramine formulation and use thereof|

---

RU2747401C1|2020-06-22|2021-05-04|Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный университет"|Method for preparation of pharmaceutical dosage forms based on methyl methacrylate copolymers|

法律状态:
2018-01-23| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|

---

2018-04-10| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2019-01-29| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |

---

2019-03-06| B06T| Formal requirements before examination [chapter 6.20 patent gazette]|

---

2021-03-23| B06A| Patent application procedure suspended [chapter 6.1 patent gazette]|

---

2021-07-06| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2021-07-27| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/02/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |

优先权:

---

申请号 | 申请日 | 专利标题

---

EP10305179.3|2010-02-23|

---

EP10305179|2010-02-23|

---

PCT/EP2011/052682|WO2011104275A1|2010-02-23|2011-02-23|Formulations for oral delivery of adsorbents in the gut|

---